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Abstract 
 Gardasil® – the vaccine was first thought to be a medical breakthrough in the fight 
against cancer, but it quickly became plagued with controversy.  Despite wide media coverage, 
little attention has been paid to today’s health care professionals who are ultimately responsible 
for prescribing the vaccine, and who may be the most knowledgeable about it.  The present study 
seeks to expand on previous literature by investigating health care providers’ current beliefs and 
practices with the human papillomavirus (HPV) immunization.  It is essential that more recent 
research be performed in order to encompass current views of the vaccine, post FDA-approval. 
 Data was collected through open-ended interviews with nine health care providers, 
including MDs and APRNs, and family practice, obstetrics-gynecology, and pediatrics.  The 
interview guide included major topics such as demographics, personal practices and opinions, 
perceptions of patients and guardians, and opinions on important controversial issues.  Major 
themes and ideas were then found among their responses through qualitative analysis. 
 Results from the data show that providers’ attitudes and behaviors are relatively uniform.  
Every provider currently administers and strongly supports the vaccine.  Although many 
expressed that beginning immunization at age nine seemed young, none opposed administering it 
at that age.  It was completely dependent upon the patients’ sexual history and the overall 
demographics of their patient population.  Some providers even expressed a desire to vaccinate 
outside of the FDA recommendations, to include boys and older females.  Evidence-based 
research and experience with treating cervical cancer were cited as the main reasons for 
supporting the vaccine.  When asked about the controversial topics, no providers felt that 
motives of pharmaceutical profit were relevant, and none believed that the vaccine would 
promote sexual activity.  Mandates were the only topic to receive varying opinions.  
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LITERATURE REVIEW 
Introduction 
 The focus of this thesis is on the attitudes, opinions, and practices of physicians (MDs) 
and nurse practitioners (APRNs) with Gardasil®.  Gardasil® is a newly approved immunization 
which has recently received a great deal of attention in the media.  The vaccine protects 
recipients from four strains of the most common sexually transmitted infection; human 
papillomavirus (HPV).  I will first give a brief history of immunization and vaccines, followed 
by a description of HPV and other STDs.  Finally, I will review the literature as it relates to the 
controversies surrounding Gardasil® and the attitudes and opinions of the major groups involved 
in HPV vaccination.
Immunization and Vaccines 
 Infectious and parasitic diseases have affected humanity for as long as anyone can 
remember.  The significant burden and devastation caused by this seemingly endless number of 
illnesses is combated by the medical community through the use of therapies, medications, and 
other forms of treatment.  However, the astronomical health care costs associated with both 
curing and treating medical conditions, combined with the severe emotional and psychological 
impact of said diseases (Aneshensel, Frerichs & Huba, 1984), present society with an even 
greater battle. 
 Enter; preventive medicines – rather than focusing on the acute or chronic treatment of 
disease, work to prevent it from occurring in the first place.  Immunizations are a prime example 
of this concept.  According to Payette and Davis (2001), “The goal of a vaccine is to induce 
immunity to an infectious disease without having to suffer the pathogenesis associated with 
natural infection” (p. 241).  The majority of licensed human vaccines contain a weakened or 
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dead form of the invading virus or bacteria.  Even though these forms cannot typically induce the 
illness, the body still recognizes the disease germ and is able to make antibodies against it, 
without having to actually fight it off.  If and when the real disease germs enter the body, the pre-
made antibodies will immediately know how to destroy them without risk of infection (Center 
for Disease Control and Prevention, 2001). 
 With that being said, vaccines have been responsible for the reduction, and in some cases 
complete elimination of infectious diseases all over the world (Bloom & Lambert, 2003).  Stern 
and Markel (2005) poetically describe the grim reality of certain illnesses that were once 
unchecked by immunization, “The gasping breath and distinctive sounds of whooping cough; the 
iron lungs and braces designed for children paralyzed by polio; and the devastating birth defects 
caused by rubella…” (p. 611).  These are only a few of the diseases that once plagued society.  
Smallpox, measles, tetanus, and diphtheria are also diseases which are now successfully 
vaccinated against.  Greg Zimet, professor of pediatrics and clinical psychology at Indiana 
University School of Medicine, states “When you consider that only a century ago infant 
mortality in the United States was 20 percent and another 20 percent of kids died before the age 
of 5…the critical role that compulsory vaccination plays is clear; the infant mortality rate today 
is less than 1 percent” (Houppert, 2007, p. 18). 
 However, such an overwhelming statistic seems to be slowly forgotten, as more and more 
parents are refusing to vaccinate their children.  Zimet goes on to explain, “Vaccines are their 
own worst enemy.  When they work, they reduce the element of risk to almost negligible.  Who 
knows anyone who has ever had diphtheria or polio today?  Take the deadly diseases so far out 
of the equation, and these parents will focus on what the vaccine’s side effects may be” 
(Houppert, 2007, p. 18).  Despite the fact that no scientific evidence has found truth in the 
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severe, debilitating, and sometimes lethal claims being made about immunizations (Omer, 
Salmon, Orenstein, deHart, & Halsey, 2009), more and more U.S. children are no longer being 
vaccinated, and there are already signs of increasing illnesses because of it. 
 Among all of this controversy, researchers continued pressing to find novel vaccines that 
would have important and positive impacts on public health.  They began investigating a whole 
new category of illness which might be prevented through immunization; sexually transmitted 
infections. 
Sexually Transmitted Infections 
 Sexually transmitted infections (STIs), also known as sexually transmitted diseases, are 
currently a huge issue, not only in the United States, but worldwide.  According to the American 
Social Health Organization (1998), the estimated total number of people living in the U.S. with a 
viral STI is over 65 million, and every year there are at least 19 million new cases of STIs.  More 
recently, the Centers for Disease Control and Prevention (CDC) (2007) found that in 2007 alone, 
over 1 million cases of chlamydia were reported; this is the largest number of cases ever reported 
to the CDC for any condition.  There was also a reported 355,991 cases of gonorrhea and 11, 466 
cases of syphilis; a number that was once on the decline, yet has been increasing every year since 
2001. 
 These STIs are the only ones actually required to be reported to the CDC.  There are 
countless other sexual diseases invading the population that go undocumented.  It is estimated 
that the most common sexually transmitted disease currently affects an astounding 20 million 
Americans, and another 6.2 million become infected each year (Centers for Disease Control and 
Prevention, 2008).   This virus is known as human papillomavirus (HPV). 
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Human Papillomavirus, Cancer, Vaccination 
 According to Zimet, Shew, and Khan (2008), HPV consists of more than 100 different 
types.  Of those 100, about 40 are passed on through sexual contact, affecting the anogenital 
areas.  It is estimated that HPV causes about 90% of genital warts (types 6 and 11), and 70% of 
cervical cancers (types 16 and 18).  Despite a high HPV prevalence rate, most women will not go 
on to develop cervical cancer.  Regardless, the National Cancer Institute estimates that in 2009, 
there will be 11, 090 new cases of cervical cancer, and over 4,000 deaths from the disease caused 
by HPV. 
 In terms of prevention, the wide spread use of Pap smears has allowed healthcare 
providers to find abnormal cell formations in the cervix, which can then be treated before turning 
into cervical cancer.  However, false-negatives can be common due to a variety of possible errors 
(Roberts, Gurley, Thurloe, Bowditch, & Laverty, 1997).  So how can abnormal cells be 
prevented in the first place?  Immunization. 
 Gardasil® is a vaccine which protects against the four types of human papillomavirus 
most commonly linked to genital warts and cervical cancer.  It is given in three doses, over a six 
month period.  Gardasil® was FDA-approved in June of 2006, and is currently recommended for 
females between the ages of 9 and 26. 
Previous Literature 
The Gardasil® Controversy 
 Coming about in an age when immunizations are being questioned by some, Gardasil® 
has only added fuel to the debate. What initially was considered a wave of hope in the ongoing 
fight against cancer quickly became plagued with controversy.  According to Karen Houppert 
(2007), “Today, as thirty-one state legislatures consider mandating the vaccine for middle school 
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girls, skepticism about the wisdom of embarking on this swift and widespread inoculation 
program has bubbled up from critics who span the political spectrum” (p. 17).  Such arguments 
stem from some abstinence-only believers who claim that the disease is a result of lifestyle 
decisions, and therefore cannot be mandated, as opposed to say, a chicken pox or measles, 
mumps, rubella vaccine.  Also, there is a debate that the vaccine will lead to sexual promiscuity, 
in which the common idea that ‘talking about sex, leads to sex’ again arises.  There are also 
many critics of Merck & Co. who claim that the company is pushing the vaccine only on the 
grounds that they stand to make $4 billion a year from this particular pharmaceutical, and are in 
no way considering women’s health and safety.  From this stems other beliefs that it is too soon 
to tell whether or not the drug has any serious side effects or is even truly effective. 
 Although the media have extensively covered these debates, there is far less scientific 
research available to determine how prevalent such arguments are, or how they are impacting 
acceptance of the vaccine.  When the FDA came out with recommendations for girls as young as 
9, there was an immediate questioning of the implications.  As far as sexuality, nothing has been 
published thus far looking at whether or not the vaccine has caused recipients in the last three 
years to have sex earlier than they normally would have, or if it had any impact whatsoever on 
their views of sexual activity.  There has, however, been previous research on other forms of STI 
prevention (Kirby, 2002; Raine, Harper, Leon, & Darney, 2005; Zelnik & Kim, 1982).  All 
studies found no evidence to support the idea that these programs led to earlier or riskier sexual 
intercourse.  More extensively, a literature review by Baldo, Aggleton, and Slutkin (1993) 
looked at 19 studies which examined sexual behavior of high school and/or college students who 
have received sexual education across multiple countries.  Not only did none of the studies 
indicate that the education led to an earlier onset, or more frequent sexual activity, but a number 
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of studies found just the opposite – that sexual education in fact caused a delay in the onset of 
sex or a reduction in sexual activity overall.  Based on these findings, it seems that STI 
prevention through the use of an HPV vaccination would not lead to sexual promiscuity. 
 There have also been arguments claiming that the vaccine is neither safe nor effective.  
However, there has been a multitude of research suggesting otherwise.  The vaccine 
demonstrated 100% efficacy in preventing warts and vaginal dysplastic lesions, and was 98% 
effective in preventing high-grade cervical lesions (e.g., Villa, Costa, Petta, Andrade, Ault, 
Giuliano, et al., 2005; Koutsky, & Harper, 2006; Future II Study Group, 2007; Garland, 
Hernandez-Avila, Wheeler, Perez, Harper, Leodolter, et al., 2007).  These same studies also 
found the vaccine to be safe.  In clinical use, any serious adverse effects that were reported were 
analyzed by the FDA and CDC and later found to be inaccurate.  These agencies issued a 
statement in July of 2008, “Based on ongoing assessments of vaccine safety information, the 
FDA and CDC continue to find that Gardasil is a safe and effective vaccine.  The benefits 
continue to outweigh the risks… This vaccine is an important cervical cancer prevention tool.” 
 However, there is still an issue regarding the actual length of efficacy.  The vaccine has 
only been FDA-approved for about three years, with research dating back to clinical trials before 
approval as well.  Studies have demonstrated a sustained efficacy for at least five years (Harper, 
Franco, Wheeler, Moscicki, Romanowski, Roteli-Martins, et al., 2006; Villa, Costa, & Peta, 
Andrade, Paavonen, Iverson, et al., 2006; Ault, 2007), which is how long research on the vaccine 
has been underway.  There have been other studies as well which demonstrated an estimated 
efficacy of 12 years or more (Fraser & Tomassini, 2007), and another which discovered an 
immune response normally found in vaccines with a long lasting efficacy (Olsson, Villa, Costa, 
Petta, Andrade, Malm, et al., 2007).  Regardless of what goes on in the media, evidence-based 
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research has found that Gardasil® is both safe and effective in preventing genital warts and 
cervical cancer in females age 9-26. 
 Populations outside these FDA guidelines are also being studied to see if they might be 
included.  Males are carriers of HPV, and they pass it on to their partners during sexual 
interaction (Dunne, Nielson, Stone, Markowitz, & Giuliano, 2006).  While they cannot develop 
cervical cancer, anogenital warts are frequently presented.  Nielson, Flores, Harris, Abrahamsen, 
Papenfuss, Dunne, Markowitz, and Giuliano (2007) examined 463 men age 18 to 40, and found 
that 51.2% were positive for at least one oncogenic or nononcogenic HPV type based on samples 
from multiple anogenital areas.  Furthermore, studies have also found that HPV type 16 may lead 
to penile, anal, and head and neck cancers.  It was found that among a small sample of males 
with penile carcinoma, 77.5% had HPV (Pascual, Pariente, Godinez, Sánchez-Prieto, Atienzar & 
Segura, 2007).  Studies are currently underway to determine the safety and efficacy of Gardasil® 
among males, in the hopes that they too will be approved for vaccination.  Thus far, research 
indicates that the vaccine stimulates a strong immunogenic response and has no significant safety 
issues in men (Block, Nolan, & Sattler, 2006). 
 Women over age 26 are another population that might benefit from HPV vaccination.  In 
January of 2009, Gardasil® was again denied approval for this population.  However, the issue is 
based on cost-effectiveness.  The vaccine’s efficacy drops greatly once females have already 
been exposed to HPV, so the point is to catch females before they engage in any sexual activity 
(Krauskopf & Pierson, 2009).  Regardless, if a female is virginal at any age, or has not gotten 
HPV yet, the vaccine can still be effective.  Long-term clinical studies are again underway to 
provide evidence-based research supporting this age group. 
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Attitudes and Opinions of Gardasil® 
 Based on the vast amount of information being presented, whether evidence-based or not, 
it is clear that there are many different opinions surrounding the HPV vaccine.  This has 
important implications for how the vaccine is being accepted and administered.  Research is 
needed to examine the attitudes and opinions of the major stake holders in Gardasil®.  This 
includes the children, adolescents and young adults being vaccinated, the parents of those 
patients who are underage, and the healthcare providers prescribing the vaccine. 
 Previous research investigating the attitudes of adolescents and young adults found that 
they had a great interest in HPV vaccination, especially an immunization that prevents both 
cervical cancer and genital warts (Zimet, Perkins, Sturm, Bair, Juliar, & Mays, 2005; Zimet, 
Mays, Winston, Kee, Dickes, & Su, 2000; Hoover, Carfioli, & Moench, 2005; Kahn, Rosenthal, 
Hamann, & Bernstein, 2003; Boehner, Howe, Bernstein, & Rosenthal, 2003).  For instance, one 
of the studies examined both female and male acceptance of STD vaccinations among college 
students using hypothetical immunizations for genital herpes and HPV.  Researchers found an 
overall endorsement rate of 74% (Boehner et al., 2003).  Khan et al. (2003) also performed 
quantitative research, though focused on only females and the human papillomavirus.  
Ultimately, 85% indicated that they would be very or extremely likely to receive an HPV vaccine 
once it was approved.  Such research refutes earlier discussion that because Gardasil® is based 
on a sexually transmitted disease, the stigma and taboo attached to it may prevent young patients 
from wanting to receive it (Zimet, Mays, Fortenberry; 2000). 
 Parents are another important group involved in the vaccination process, especially those 
who will be making the decision for children who are not yet old enough to do so themselves.  
Despite concerns that parental refusal would be a major barrier to Gardasil® administration, 
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previous research, reviewed by Zimet et al. (2006), all found that parents expressed a moderate 
to strong interest in vaccinating their preadolescent and adolescent children against STIs (Mays, 
Sturm, & Zimet, 2004; Davis, Dickman, Ferris, & Dias, 2004; Zimet, Mays, Sturm, Ravert, 
Perkins, & Juliar, 2005; Zimet, Perkins, Sturm, Blair, Juliar, & Mays, 2005; Liddon, Pulley, 
Cockerham, Lueschen, Vermund, & Hook, 2005; Olshen, Woods, Austin, Lushkin, & Bauchner, 
2005; Dempsey, Zimet, Davis, & Koutsky, 2006; Brabin, Roberts, Farzaneh, & Kitchener, 
2006).  More research has been published since the Gardasil® FDA-approval in 2006.  Most 
studies continued to find that the majority of parents wanted to have their children vaccinated 
against HPV specifically (Constantine & Jerman, 2007; Brabin, Roberts, & Kitchener, 2007; 
Woodhall, Lehtinen, & Verho, 2007).  A common theme among the minority of parents who 
opposed the vaccination concerned issues previously discussed above; sexual promiscuity, 
feeling their child would not be infected, and worries about efficacy and safety.  Perhaps 
providing parents with evidence-based research regarding these concerns would lead to an even 
greater acceptance rate.  Overall, this wide mixture of studies ranged from pre- to post- FDA-
approval, was performed in various countries and across multiple samples, and included both 
quantitative and qualitative research. 
 The next major group is an essential part of the immunization process.  Healthcare 
providers are an important population to study because they must decide if they are going to 
discuss, recommend, prescribe, and administer Gardasil® to incoming patients.  Regardless of 
whether or not the children, young adults and guardians want it, healthcare providers ultimately 
determine if they can have it.  In addition, Smith, Kennedy, Wooten, Gust, & Pickering (2006) 
and Gonik (2006) found that healthcare providers have a large influence on a parent’s choice to 
vaccinate their children, including those who believe that vaccines are unsafe. 
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 The majority of previous published research looking at provider attitudes and opinions 
was performed prior to Gardasil’s® FDA approval.  It was quantitative survey analysis, and most 
studies only focused on one healthcare profession at a time.  Of the endless number of healthcare 
providers available, nurse practitioners and physicians specializing in pediatrics, family/internal 
medicine, and obstetrics-gynecology are the ones most involved in the actual prescription and 
vaccination of Gardasil®. 
 One of the first studies performed with regards to healthcare providers and general STI 
vaccination was also the only study to look at the attitudes and beliefs of nurse practitioners.  
Mays and Zimet (2004) explained that, “Future successful sexually transmitted infection (STI) 
vaccine programs will depend on health professionals’ readiness to vaccinate adolescents” (p. 
428) – a purpose that will be echoed throughout the rest of the research on medical professionals.  
Participants in the study rated 13 hypothetical vaccine scenarios which varied according to the 
type of STI infection, the age and gender of the patient, and endorsement of the vaccine by a 
major organization.  The researchers concluded that nurse practitioners would be willing to 
recommend STI vaccinations when they became available.  Medical organization endorsement 
was one of the main factors mediating vaccine uptake.  Interestingly, gender of the patient did 
not influence whether or not providers would recommend the vaccine.  Also, there was a 
preference to vaccinate 17 year olds, as opposed to 11 year olds. 
 This study laid the groundwork for all future research regarding the upcoming HPV 
vaccine.  It is important to note, however, that HPV was not included in this particular study; 
rather genital herpes and HIV.  Regardless, the finding that older adolescents were preferred over 
younger ones will continue to be a common finding.  This has important implications for the 
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future, considering the rate of sexual activity and STI prevalence among a younger population 
(Centers for Disease Control and Prevention, 2002; Burnstien, Gaydos, & Diener-West, 1998). 
 Gynecologists’ were the next group of healthcare professionals to be studied.  Again, 
only one study was performed on this particular medical practice. Raley, Followwill, Zimet, & 
Ault (2004) looked directly at HPV vaccine scenarios, and they found similar results.  
Organizational endorsement was considered the most important factor in determining 
predisposition to provide the vaccine, followed by vaccine efficacy, and age of the patient.  Once 
again, there was a preference to vaccinate at age 17 and a strong disinclination to vaccinate at 13. 
 The only study to specifically focus on family physicians was performed by Riesdesel, 
Rosenthal, Zimet, Bernstein, Huang, Lan, and Kahn (2005).  This study went a step further in 
assessing the issue of gender.  They found that these physicians had a higher intention to 
recommend to girls over boys, a finding that differs from the STI recommendations of nurse 
practitioners.  HPV vaccination may be perceived differently from other STIs included in their 
study.  Despite this difference, other findings remained consistent with previous research.  There 
was an overall willingness to vaccinate against HPV; however, older adolescents were preferred 
over younger ones. 
 The final group of healthcare providers involved in the immunization process is 
pediatricians.  This profession, unlike the others, was studied much more extensively as opposed 
to just a single research study.  Of the quantitative studies taking place before FDA-approval, all 
found the common theme that the majority of pediatricians strongly endorsed the vaccine.  
Again, they were most likely to recommend the HPV vaccine to older patients rather than 
younger, and more often to girls over boys (Kahn, Zimet, Bernstein, Riesdesel, Lan, Huang, & 
Rosenthal, 2005; Daley, Liddon, Crane, Beaty, Barrow, Babbel, Markowitz, Dunne, Stokley, 
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Dickinson, Berman, & Kempe, 2006).  These studies also found that providers felt parents may 
be a significant barrier in vaccination.   
 Similar quantitative studies were performed directly after the June 2006 FDA approval; 
however, they still mainly measured intent to prescribe rather than actual practices and behaviors 
(Feemster, Winters, Fiks, Kinsman, & Kahn, 2008; Ishibashi, Koopmans, Curlin, Alexander, & 
Ross; 2008).  Interestingly, Feemster et al. (2008) found that 78% of respondents reported being 
extremely likely to recommend the vaccine to 11-12 year old girls, and 18% were somewhat 
likely.  These findings vary greatly from the pediatric studies performed a year or more before 
FDA-approval. 
 The only qualitative study found was also based on pediatricians.  Kahn, Rosenthal, 
Tissot, Bernstein, Wetzel, and Zimet (2007) utilized semistructured individual interviews to 
assess attitudes and intentions regarding HPV immunization for 31 pediatricians in three 
Midwest states.  Again, physicians felt that parents might be a large barrier to vaccination, 
despite previously mentioned research that found a relatively high rate of acceptance from 
guardians.  Also, this study, which was performed closer to the FDA-approval time period, found 
that only half preferred vaccinating patients over age 15. 
 Based on all the preceding research, it appears that as time elapsed, healthcare providers 
became more likely to administer the vaccine to a younger population.  Finally, there was also 
only one qualitative pre-FDA approval study that looked across physicians from all three 
different backgrounds; obstetrics-gynecology, family physicians, and pediatricians (Duval, Gilca, 
McNeil, Dobson, Money, Gemmill, Sauvageau, Lavoie, & Ouakki, 2007).  Researchers found 
some similarities, but also interesting differences.  Overall, 95% of physicians thought the 
vaccine should be given before first sexual encounter.  When asked if they ultimately will 
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prescribe HPV vaccines, 93.6% of gynecologists, 90.8% of family physicians, and only 77.1% of 
pediatricians said they would – percentages which correlated with the amount of correct HPV 
knowledge known.  It is also important to note that this study was performed in Cananda; there 
are no published studies to date that compare different providers in the United States. Such 
findings will be important to expand upon in future research. 
 It is clear that more research is needed to investigate the attitudes and behaviors among 
healthcare providers about HPV vaccination as it is adopted into the medical community.  The 
present research expands on previous literature by performing a study almost three years into the 
clinical usage of Gardasil®, after its FDA-approval in 2006.  It will be important to see if 
practitioners are continuing to become more accepting of the vaccine and whether or not they are 
actually administering it in their practice.  Also, changes in the gender and age accepted for 
immunization may be changing as well, presenting an entirely new phenomenon in the 
Gardasil® debate.  The present study will also be based on qualitative methodology rather than 
the overwhelming amount of survey analysis done in the previous studies.  Similar to the 
previous research by Duval et al. (2007), an open-ended interview guide will allow providers to 
expand on their thoughts without being limited to a pre-determined set of answers.  This may 
allow for interesting findings about provider attitudes and beliefs that were not able to be 
captured in surveys and questionnaires.  Finally, the present study will be looking across the 
three major healthcare providers involved in the Gardasil® immunization process, while also 
expanding to include nurse practitioners – a population that was only studied once, and not 
specifically with regards to the HPV vaccine (Mays et al., 2004).  It is essential that we obtain a 
more current view of healthcare providers and their thoughts and behaviors regarding their 
patients and Gardasil®. 
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METHODS 
 
Sample Criteria 
 Although many medical professionals can give medications or injections, only physicians 
and nurse practitioners can prescribe them, and therefore they were the only providers included 
in the criteria.  Inclusion criteria for the study stated that participants are currently practicing in 
the state of Connecticut, English-speaking, and certified to prescribe medications, specifically 
the HPV vaccine, Gardasil®.  Of the physicians and nurse practitioners, only those specializing 
in pediatrics, internal/family medicine, and obstetrics-gynecology were included.  These three 
specialties deal most directly with counseling and administering Gardasil® to patients.  Any 
respondents who did not fit these criteria were to be excluded, though no one outside of these 
restrictions contacted the principal investigator to be interviewed.  Age, gender, sexual 
orientation and ethnicity were not limited in this study. 
Participants 
 Participants for this study included nine healthcare providers practicing in the state of 
Connecticut.  Three were located near the Waterbury area, and six others worked in the towns 
and cities surrounding Mansfield, Connecticut.  Three were nurse practitioners and six were 
physicians.  By specialty, two were in pediatrics, three in obstetrics gynecology, and four in 
internal/family medicine.  Ages ranged between 35 and 71, with three males and six females.  
Table One, below, summarizes the demographic characteristics and also includes the typical 
patient age range each provider sees.  One internal/family provider treats patients in the pediatric 
age range along with those over age 20. 
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Table One: Participant Characteristics 
Participant Gender Age Profession Practice Patient Ages 
1 Male 63 M.D. Pediatrics 0-22 
4 Male 71 M.D. Pediatrics 0-20’s 
6 Male 45 M.D. Obstetrics Gynecology Preteen-90’s 
3 Female 43 A.P.R.N. Obstetrics Gynecology 11-82 
5 Female 35 A.P.R.N. Obstetrics Gynecology Teen-90’s 
7 Female 49 A.P.R.N. Family/Internal 16-70 
2 Female 66 M.D. Family/Internal 14-97 
8 Female 49 M.D. Family/Internal 18-24 
9 Female 53 M.D. Family/Internal 0-90’s 
 
Procedure 
 To recruit participants for this study approximately 200 letters and flyers, approved by 
the University of Connecticut IRB (#H08-308), were mailed out to practices in and around the 
areas of Mansfield and Waterbury.  Based on business listings in the Connecticut Yellow Pages, 
only those providers meeting the designated criteria were specifically contacted.  The letter 
outlined the current controversies over Gardasil®, the purpose and qualitative nature of the 
study, as well as how to get in touch with the primary investigator.  It was then up to the 
providers to contact the researcher if they wanted to participate.  Providers were not paid for 
their participation in the study. 
 Once a line of contact was established, using telephone or email, the provider specified 
whether he or she would like to meet in person or over the phone.  She or he then designated a 
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date, time, and place which was most convenient to conduct the interview, based on estimation 
that it would take between 15-25 minutes depending on how in-depth the provider wanted to be 
in his or her responses.  For those interviews which took place in person, a consent form was 
given at the meeting for the provider to read and sign.  Those who wished to discuss the study 
over the phone were faxed a copy of the consent form and asked to fax it back before the 
interview. 
 Immediately prior to the interview participants were re-informed that the study was going 
to be audio-taped with a digital recorder, their participation was completely confidential, and that 
they did not have to answer any questions with which they felt uncomfortable.  During the 
interview, all participants were given as much time as they needed, and could address any 
concerns or questions about the study.  
 During the interview process, the researcher asked all questions in the order that they 
appeared on the guide.  Due to the open-ended nature of the study, some providers provided an 
answer to another question while answering an earlier one.  When a question was reached that 
had already been partially or fully answered, the researcher indicated so, and then proceeded to 
read the question and ask if they wanted to expand more, or were comfortable with what they 
had said previously. 
Measure 
 A qualitative interview guide was used to collect information; it was approved by the 
University of Connecticut IRB before the recruitment process.  Questions were open-ended to 
ensure that providers were able to explore all different aspects of the HPV vaccine.  Due to the 
qualitative nature of the research, and because it was being performed approximately two years 
into actual clinical usage of Gardasil®, there were no specific interview guides in the published 
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research that could be used.  Based on what has been done, the principal investigator prepared a 
list of possible questions which were reviewed by peers and professors at the university.  The 
final interview guide consisted of 22 main questions, some of which also included sub questions.  
They were then examined for common themes in order to categorize them more efficiently.  The 
following description contains two examples for each main group of questions asked.  Appendix 
A contains a full copy of the interview guide. 
The first was demographics and general information about the providers’ medical practice, such 
as: 
General Information: 
 -Age and gender? 
 -Medical certification/specialize in? 
The next segment focused on the healthcare provider’s own personal opinions and practices 
regarding Gardasil®, for example: 
The Healthcare Provider: 
 -Do you currently administer the HPV vaccine to your female patients?  What has led 
 you to this decision? (Probe; religion, personal experience, companies, peers, research). 
 -Do you bring up the vaccine with female patients/their guardians on your own, or do you 
 wait for them to ask about it before voicing your opinion?  Why? 
The third section covered their experiences with patients, such as: 
The Patients: 
 - Why do you think some patients and/or guardians choose not to get the vaccine?  Or 
 have you experienced any who did not want it?  Do you agree with any of these reasons 
 or do you have any of your own? 
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 - Have your patients ever experienced any negative side effects which they believe 
 occurred because of taking the vaccine? 
The final questions attended to more controversial issues that have come about in the media, e.g.: 
Controversial Issues: 
 - If you do administer the vaccine, at what age or age range do you think females should 
 start getting Gardasil®?  What led you to choose this age (range)? Do you agree with the 
 FDA beginning the age range at 9? Why or why not? 
 - Do you believe administering the vaccine to females, who are not yet sexually active, 
 will cause them to have sexual intercourse before they normally would have, had they not 
 had the vaccine?  Does your opinion change depending on the age of the female? 
Data Analysis 
 All interviews were kept on the student researcher’s digital recorder until the last 
interview was obtained to ensure confidentiality.  Once the interviews were ready for analysis, 
they were uploaded onto the investigator’s computer and transcribed verbatim.  For qualitative 
analysis, the transcripts were read and examined to find main themes among the providers’ 
responses.  Similarities and differences were uncovered regarding healthcare provider practices, 
opinions, and experiences with Gardasil®, and then these ideas were categorized into the major 
themes.  These topics were different from the four interview sections since the provider 
responses were much more specific, and information consistently came about that had not 
initially been accounted for.  Anita Garey, honors advisor, communicated with the principal 
investigator about qualitative analysis.  Also, a previous study on provider HPV vaccine attitudes 
was used as a guide for investigation, as it was the only study to use a qualitative interview 
approach (Kahn et al., 2007).  
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RESULTS 
 After conducting and analyzing the interviews of nine different healthcare providers, 
major themes surfaced with regards to their attitudes, practices, and experiences with the 
Gardasil® vaccine.  It is important to remember that providers varied by profession, area of 
specialization, and gender.  Yet, the first major finding was that provider responses were rather 
uniform across most topics, with a few exceptions.  That is, being a physician or an APRN in a 
particular specialty, or being male or female, did not consistently affect reported attitudes and 
behaviors. 
 Beyond that major point, in order to describe these results efficiently, I will present them 
within six major categories or themes; (1) provider attitudes and opinions, (2) provider practices, 
(3) thoughts on the FDA guidelines of 9-26 year old females, (4) experiences and beliefs 
surrounding patient/guardian refusal, (5) providers’ own reasoning for vaccination, and (6) 
controversial topics.  These thematic categories are further broken down into sub-themes where 
appropriate.  Quotes are also used to better illustrate how the providers (1-9) felt about specific 
issues throughout the interview, and the providers’ profession and specialization will be provided 
for further comparative study. 
1) Providers’ General Attitudes and Opinions Regarding Gardasil® 
Initial Introduction of the Vaccine 
 Gardasil® was approved for prescription by the Federal Drug Administration in July of 
2006.  When asked how providers initially felt about the HPV vaccine around this time, answers 
were mainly positive.  Two providers who did not go into much detail for this particular question 
mentioned that they felt the vaccine was a great advancement for the medical community.  
Others expanded on this point as follows: 
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 “I think that it was definitely something that I thought was a pretty incredible break 
 through, it was certainly something that was very compelling.” (5 – APRN, ObGyn) 
 
 “I knew about its development.  I was very excited about it being released.  And, like I 
 said, I think it has great clinical potential.” (6 – MD, ObGyn) 
 
One of the respondents was particularly prompt to respond to the FDA approval, mentioning a 
more personal experience with the following quote: 
 “Well, let’s put it this way; the first person who I gave it too was my own daughter.  And 
 that was, I believe September 20th ’06!” (9 – MD, Family/Internal) 
 
Alternatively, a pediatrician expressed a somewhat different opinion: 
 “As a physician who deals with this all the time, you have to start from a skeptical point 
 of view.  And then you leave it out there. I won’t be the first to adopt, I won’t be the last.  
 It has to be out there about a year maybe two to get an idea.” (4 – MD, Pediatrics) 
 
This difference in initial uptake of the vaccine is an interesting finding.  Several non-pediatric 
providers mentioned at points in their own interviews that they felt pediatricians were much 
slower on accepting and administering the vaccine at first.  These two providers explain: 
 “First they [pediatricians] weren’t giving it out, and I was giving it out, and they weren’t 
 too quick on the uptake.  The GYNs were, we were, but the pediatricians took a little 
 while before they started to do it.  I think they all do it now, but they were a little hesitant 
 at first.” (9 – MD, Family/Internal)  
 
 “Many times now I bring it up and the patients will say ‘Oh I already got that!’  This 
 for me is fairly new in the last year or so, that I think the pediatricians have become much 
 more active in getting their patients vaccinated.” (3 – APRN, ObGyn) 
 
The other pediatrician in the study unfortunately did not mention when he began vaccinating his 
patients.  Pediatrics aside, this slight sense of skepticism was voiced by a couple of the other 
providers as well, though none stated exactly when they adopted the vaccine into their clinical 
practice.  One of the nurse practitioners mentioned it in a different light: 
 “I think a little bit of wait-and-see attitude.  I think that I was hopeful that it would be a 
 good thing for patients, because I do a lot of women’s health, so skepticism in the sense 
 that I always wait to see what the downstream effect of it will be.” (5 – APRN, 
 Family/Internal)  
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Similar beliefs were mentioned by another APRN in obstetrics gynecology who claimed to have 
some reservations.  Overall, none of the providers had any explicitly negative comments or 
opinions of the vaccine during its FDA approval. 
Current Feelings; Approximately Two and a Half Years since Approval 
 When asked if their views have changed at all in the short time since its introduction, 
most of the providers who had initially expressed support and praise for the vaccine stated that 
they still felt the same way.  All those who had mentioned any kind of skepticism claimed that 
they now fully support the vaccine in their practice.  A female provider was very adamant about 
the efficacy and safety shown in the research particularly and also mentioned that she felt 
Gardasil® should be considered along the same lines as any other vaccination.  She explains in 
the following quote: 
 “I had my reservations, as I do whenever there’s a vaccine, same thing with chicken pox, 
 and meningitis, and so forth… Until I got a chance to read the research, and recognized 
 that it was a fully tested and FDA approved medication.  My views have changed not 
 because I didn’t recognize that HPV was an issue, because HPV has always been an 
 issue.  My views changed once I saw the data of the ability of the HPV vaccine in 
 preventing HPV, which is almost 100%!” (3 – APRN, ObGyn) 
 
The pediatrician (4) went on to explain how his practice has changed quite a bit: 
 “It took a good 18-20 months for me to adopt.  Now we go through about 3-4000$ worth 
 of vaccine on about a 6-10 week basis, so it’s a lot!” (4 – MD, Pediatrics) 
 
Another provider mentioned that she now felt like a stronger advocate for the vaccine since the 
initial release, and stated that she has even just gotten used to it in her everyday practice (8 – 
MD, Family/Internal).  So although there were some differences among the providers as far as 
their initial feelings, all participants currently believe the vaccine is a great medicinal 
development for their patients. 
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Beliefs about Vaccine Safety and Efficacy 
 When asked about Gardasil’s® safety, every participant in the study was quick to state 
that they felt it was safe to give to patients.  Responses included everything from “Yes” and 
“Absolutely,” to more in-depth responses, such as: 
 “After all these years and the thousands of patients who have received it, it is safe to 
 administer.” (4 – MD, Pediatrics) 
 
 All providers also felt that the vaccine was effective in preventing cervical cancer, with 
similar responses to those listed above.  There was some variation, however, when discussing the 
long term efficacy.  Many providers mentioned within their interviews that they were still unsure 
about how long the vaccine would be useful, and this was based on the fact that the vaccine just 
has not been out long enough to see if it will last a lifetime, or if booster shots will be needed.  
One provider explained: 
 “Well, as much as the data shows it’s effective.  What are we, at seven or eight years, at 
 2006 there had been about five years of data.  So, you know, here we are, and it still 
 looks effective at this point, so to that extent, yes.  There’s still a question of the long 
 term efficacy, but you know, that’s to be known.” (5 – APRN, ObGyn) 
 
The issue of long term efficacy is brought up in more depth later on when discussing patient and 
guardians’ attitudes towards the vaccine.  To date, however, all the providers expressed a similar 
belief that the vaccine was both safe to give to patients, and effective in preventing cervical 
cancer linked to HPV. 
2) Providers’ General Clinical Practices 
Administration of the Vaccine 
 As foreshadowed by the above discussion of current opinions and attitudes, all 
participants stated that they currently administer Gardasil® to their female patients on a regular 
basis. 
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 Expanding on the idea of safety, none of the providers experienced any severe side 
effects in their patients when the vaccine was administered correctly, that is, one shot to start, 
another shot two months later, and a final shot six months after the first.  There was an instance 
mentioned by one participant when the vaccine was not given correctly by a fellow nurse 
practitioner: 
 “We had one, and it was actually not my patient, it was one of the other nurse 
 practitioners in the office, and it was when we first started giving the vaccine and she 
 initially made an error and told the patient she needed to come back one month instead of 
 two months, so the patient got her second Gardasil® injection only like 35 days after her 
 first one and she broke out with a terrible case of shingles… Which, I think certainly that 
 her immune system was compromised beforehand; it would make sense that she might 
 have a shingles outbreak – Did it cause her to have shingles?  You know, who knows.  
 So, when the vaccine is given appropriately I have not seen anybody have any adverse 
 effects.” (3 – APRN, ObGyn) 
 
 Although this event is a serious condition, the dose was not given correctly, and the 
provider believed that there may have been an issue beforehand with the patient’s immune 
system for it to cause such a severe reaction.  All other providers either claimed that they had 
experienced no negative side effects at all, or reported some of the common side effects listed on 
the vaccine’s website.  These include feeling faint, pain, and headache.  For example, one APRN 
noted: 
 “It’s been really consistent with the research!  Which is local, the site of the injection, 
 like very small welts or some pain.” (5 – APRN, ObGyn) 
 
Some providers attributed the fainting to be more of a needle-phobia reaction, or typical reaction 
to any immunization.  One such example: 
 “We’ve really not had any, we’ve had a couple of people that have had one of the normal 
 reactions afterwards where they’ve felt faint, and lots of people feel that that has nothing 
 to do with the vaccine, that that’s just a-um, teenage response.” (2 – MD, Pediatrics) 
 
One provider also mentioned that there were some small allergic reactions to the vaccine which 
then caused the patient to stop the series.  This too is listed on the Gardasil® website as a 
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possible reaction to a type of yeast in the vaccine.  Overall, the majority of providers claimed no 
side effects whatsoever. 
Recommendation of the Vaccine 
 When asked if they actively recommend the HPV vaccine to patients, the majority of 
providers, eight out of nine, said that they did.  Only one provider stated that he did not, saying, 
 “I um, ehh not really… Most of the time we wait for them, but, I, you know what… 
 That’s not fair; our room assistants often will mention it.” (1 – MD, Pediatrics) 
 
He seemed hesitant and unsure of his answer and when asked if he wanted to explain further, he 
seemed to get somewhat defensive and immediately mentioned that there were other providers in 
the office who brought it up.  This physician was one of only two pediatricians in the study, 
which may again link back to the idea that pediatricians could be somewhat different in their 
approach to Gardasil®.  The other pediatrician, who had mentioned waiting about a year and a 
half before vaccinating, does actively recommend the vaccine at present and was very adamant 
about doing so. 
 Other providers, all of whom took an active role in recommending, mentioned some of 
the ways in which they did so.  These examples included simply bringing up the vaccine, as one 
physician explained: 
 “Well, I ask them if they’re aware that there’s a vaccine available that could prevent HPV 
 infection and subsequent possibility of cancer.  And then I inform them and I give them 
 the choice of if they would like to do that or not, and sometimes I’ll say, ‘You know, you 
 don’t have to decide now, but the next time you come back let’s talk about it again.’”  
 (2 – MD, Family/Internal) 
Others reported using specific tactics which aimed to convince the patients that Gardasil® was a 
good investment, which was demonstrated by a gynecological physician who brought up the 
trouble cervical cancer can cause (a concept that is addressed again later on when discussing why 
providers choose to vaccinate): 
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 “I do so by saying that the HPV vaccination and it’s infection are endemic at this time, 
 and that it can lead to not only cancer of the cervix, but a whole bunch of other slew of 
 things that lead to more visits to me, that lead to more procedures by me, that are not
 fun, so!” (6 – MD, ObGyn) 
 
Another provider tactic was information.  This provider describes how she tries to influence 
guardians to have their daughters vaccinated: 
 “I try to tell parents that the whole point is to catch them before they’re sexually active, 
 not when they become sexually active, and actually I try to even influence them a little bit 
 more by saying… Somewhere in the literature I think there’s evidence that it actually 
 works a little bit better in the younger age group.  So I try to influence some of those 
 parents who think their kid is too young, when they’re really 13, 14, or 15, that there’s 
 evidence to show that the vaccine works even better the younger you get it.  I don’t 
 know, I mean 1-2%, but even so, you know sometimes with someone who has got some 
 negative ideas you have to use whatever you can.” (9 – MD, Family/Internal) 
 
This same provider cited the use of pamphlets and informational sheets around her office: 
 “Oh, I have lots of literature in the office, from the company first of all, that’s all over the 
 office.  Second of all, when there’s a patient who I know hasn’t had it, and is at an age 
 where they can get it, I talk it over with them and the mother.”  (9 – MD, 
 Family/Internal) 
 
 The second half of her statement brings up another important idea that came up in the 
interviews.  When asked if they brought up the vaccine on their own, or waited for patients 
and/or guardians to ask about it first, the majority of providers cited a patient’s age and sexual 
history as being the deciding factor in whether or not they even recommended it. 
Recommendation with Regards to Patient Age and Sexual History 
 A common theme that arose under the major topic of “Provider Practices” was that 
providers based their recommendation of the vaccine on the patient’s age, and to a higher degree, 
sexual history.  The importance of vaccinating children before they are sexually active was a 
huge factor that many of the providers mentioned across all disciplines.  One pediatrician noted 
that: 
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 “It’d be very unusual to see cervical cancer in the age group that we deal with 
 [pediatrics], but I mean, you’ve got to get them immunized early enough so that they can 
 have the vaccine before getting HPV.” (1 – MD, Pediatrics) 
 
This doctor seemed hesitant to mention sexual activity specifically.  Other providers went into 
more detail.  The following quotes demonstrate the commonality of this particular response: 
 “You know, if it’s a young girl who’s sexually active, I strongly encourage her to get the 
 HPV vaccine.  If I’m lucky enough to see them before they’re sexually active or I can 
 talk to their moms, I strongly encourage them to have their children get the HPV vaccine.  
 If, you know, I have a patient who is maybe young, 23, 24, but is either married or in a 
 monogamous relationship and really considers themselves not at risk any longer, you 
 know I still mention it but I may not push as hard, because I think really the people we 
 want to vaccinate are the sexually innocent.” (3 – APRN, ObGyn) 
 
 “I actively recommend it for virginal women and girls.  And that’s based on the data that 
 the efficacy is cut in half in women who are sexually active…  It’s an incredible benefit 
 to especially a girl who is virginal…  It depends on the demographics.  If they’re 40 and 
 married it’s not important at all.  If they’re virginal it’s pretty important.” (5 – APRN, 
 ObGyn) 
 
 “I bring it up.  Any patient who is in the range, hopefully before their sexual debut, so 
 that’s the ideal patient to find… It depends on their age and where they’re at.  I mean if 
 somebody is 30 and showing up after 3 kids it’s not terribly important, and they’re not 
 the ones that are most recommended for it right now.  Whereas the other patient I just 
 mentioned is right.” (6 – MD, ObGyn) 
 
 “It’s just part of the routine things that I discuss at preventive health visits, so, women in 
 their 40’s I would discuss mammography, women in the 9-26 range I would recommend 
 the HPV vaccine.” (7 – APRN, Family/Internal) 
 
Many of the providers above cited the FDA age range in their responses.  This leads directly to 
the next major theme. 
3) Provider Thoughts on the FDA Approval of 9-26 Year Old Females 
 This particular section links intricately with provider practices.  However, the FDA 
recommendation brought up specific opinions and evoked certain experiences which are better 
categorized as a separate theme.  The first subject involved beginning the age range at nine.  
Here, providers explained how they felt about it, as well as the age at which they typically started 
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vaccinating, and why.  A major finding was that most providers in this study started administered 
in the early teens, though none disapproved of vaccinating at nine.  Some did express feelings 
that it was young, yet agreed that there are certain patient populations which should be getting 
the vaccine at that age. 
Age Nine and Patient Population 
 Many providers started out by stating when they felt females should start getting 
Gardasil®, which for all was somewhere between about 10 to 13.  These comments are 
illustrative of that belief: 
 “I um, I think that they can, the easiest way to remember is to say starting with double 
 digits, when they start to be 10, and then they can get it.” (1 – MD, Pediatrics) 
 
 “Well I don’t treat them, but I would certainly start at puberty, just before puberty… 
 Because you never know when a child’s going to become sexually active and be exposed 
 to HPV, it’s unknown!” (2 –  MD, Internal/Family) 
 
 “I tend to think that the early teen years, before, again I commented on my daughter age, 
 I think that by you know 11 or 12…  I know they can start as early as 9, but I think that’s 
 a little early.”  (7 – APRN, Family/Internal) 
 
 When probed about the FDA starting their age range approval at nine, participants all 
expanded on the importance of a provider’s patient population, as demonstrated in the following 
quotes: 
 “You know, I suspect in certain populations by starting early you’re trying to capture 
 people, but I certainly think 11 or 12.  Though I’ve had patients who’ve been sexually 
 active as early as that, so I think that it’s an individual decision hopefully for parents and/ 
 or guardians to make.” (7 – APRN, Family/Internal) 
 
 “Oh I think middle school.  Like 12ish?  Hopefully that is before onset of any sexual 
 activity.  You have to know your patient population!  You may work at a poor inner-city 
 clinic and you may want to get those kids going at age eight, I don’t know.  It’s just sad 
 to think.” (8 – MD, Family/Internal) 
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Other providers jumped right into a discussion of population without being asked specifically 
about the FDA, and some mentioned possible rape or young pregnancies as a factor.  A nurse 
practitioner talked about molestation in the following quote: 
 “I think 9 is young, I do… However, I have said to mothers, you know, god forbid your 
 child is molested at 10, you know, not that they’re going to become sexually active, but 
 don’t you want to protect them from everything?”  (3 – APRN, ObGyn) 
 
This particular response can also be tied back to some of the tactics that providers use to 
convince patients and/or guardians about the benefits of Gardasil®.  Continuing with the issue of 
early pregnancies and population, some providers said: 
 “It depends on where you’re at.  Like with my kids, mainly we start administering about 
 11.  I have one mother who is a nurse who works at a low-income type clinic and they 
 give their stuff starting at exactly 9 and a half.  I asked her why, and she said she’s got 11 
 and a half year olds who are delivering babies.  So, she knows they’re active, she wants 
 to protect them.” (4 – MD, Pediatrics) 
 
 “Umm, well, 9 I agree with for certain populations where there are kids who are pregnant 
 at 11 or 12, and I think that’s why they did it.  I hope for some of the inner city 
 population who, when they’re 9, they’re really like another person’s 18!  It’s really crazy.  
 But for those people, yes I think they even need it more, because they’re starting so 
 young.” (9 – MD, Family/Internal) 
 
One nurse practitioner explained how she actually had experienced young pregnancies in her 
own practice: 
 “You know, you have to believe the public health research in terms of the age range for 
 sexual activity, and sort of maybe tailor it to your population… You know, I’ve had 
 pregnant 11 year olds.  And I see that if you’re a pediatrician or you’re looking at it from 
 a public health perspective to have a standardized time for the vaccination is probably a 
 good thing.” (5 – APRN, ObGyn) 
 
This provider also brings up other reasoning for having a young age range in the second half of 
her comment.  She mentions taking a public health perspective and seeing how a set range could 
be a good thing.  Continuing with this idea, other providers went into more detail about the 
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efficiency of having the HPV vaccine available at nine.  Two physicians explained in the 
following quotes: 
 “You know, it seems young to me when I first hear that age, I go ‘Gosh..’, and maybe
 there’s a small cadre of the population who is nearing their sexual debut at 9.  It’s also 
 though a very effective way to get to people that are still seeing their pediatricians on a 
 regular basis, and they have to get their school physicals.  So, in terms of the public 
 health means of administering an effective treatment, you’re catching a lot more of the 
 population doing it that way than waiting until they’re teenagers and neglecting their 
 health for better or worse.” (6 – MD, ObGyn) 
 
 “Yeah I don’t really usually give it at 11, so much as around 12, 13.  Um, I think most 
 kids aren’t sexually active by that time.  It depends on your population obviously, but, 
 you know I mention it when, usually there’s a 6th grade physical in Connecticut, so that’s 
 11.  I mention it at that time so that they can be primed on it and some of them say, ‘Yeah 
 let’s get a start on it!’ 6th grade and high school sophomores must come in for physicals.” 
 (9 – MD, Family/Internal) 
 
Again, the concept of focusing on one’s patient population brings up the common theme 
that providers felt patients needed to be vaccinated before any onset of sexual activity.  A couple 
of the participants even brought up their own children as examples, which adds a very personal 
aspect to their beliefs and practices.  As previously quoted, one had mentioned giving it to her 
daughter almost as soon as the vaccine was approved (9 – MD, Family/Internal).  Another 
provider mentioned waiting to get the added benefit of having a longer effect because she was 
confident that her child was not yet sexually active, as shown in the following quote: 
“You know, I have to admit I’m a parent myself; I have a 10 year old daughter, but I 
probably will wait until she’s probably 12, you know another two years, that’ll give 
another two years of data…” (7 – APRN, Family/Internal) 
 
Another nurse practitioner, who doesn’t have children of her own, spoke similarly: 
“But, you know, if I was the parent of a child who I was fairly certain was not going to be 
sexually active in the next few years I might delay it to get the added benefit of, you 
know, if it’s only good for ten years you might delay it for that reason.” (5 – APRN, 
ObGyn) 
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Finally, one of the physicians spoke of his daughter: 
“I think it’s something you give.  You know, when my daughter reaches an appropriate 
age, and right now she’s nine, so very soon, she’ll be getting it!” (6 – MD, ObGyn) 
 
These quotes in particular overlap with a major theme that will be discussed later: providers’ 
feelings and experiences with patients and/or guardians who may or do refuse the vaccine.  
Before exploring more on that issue, I’ll note other concerns that came up with regards to the 
FDA recommendations of females, 9-26.  These included the vaccination of older women, as 
well as boys.  One gynecologist explained: 
“You know, I think the recommendations that have come out are useful.  I don’t feel that 
they should be written in stone, because I think that there are opportunities to use them 
outside of those recommendations wisely and effectively.” (6 – MD, ObGyn) 
 
Women over Age 26 
 A comment that came up relatively often, without any specific questioning from the 
researcher, was the topic of older women and the HPV vaccine.  One nurse practitioner described 
a relevant experience she recently encountered that made her more aware of wanting to advocate 
for an older female population: 
“You know, I have a hard time with that because I know that the FDA chose 9-26 
because that’s the age range when we mostly can get these young girls without… But I 
just was going over a case with the doctor on a patient who is 57 years old, she was 
married for 20-odd years, got divorced, and then was alone with herself for about 10 
years.  Never had an abnormal Pap, completely normal.  She gets a new boyfriend, now 
she’s 57, she starts having intercourse with a new person who obviously has HPV, she 
shows up 6 months later with a high-grade lesion.  Now, you know, when she came in 
and she said “I’m divorced, I’m going to be sexually active again with a new partner,” 
she would have been your perfect person to give Gardasil® to!  But because she falls 
outside of that FDA range, not to say that we don’t prescribe drugs all the time outside of 
the FDA, you know off-label, but right now they’re sort of hitting us up with, ‘Well that’s 
the age range, we really don’t have enough to give it to everybody.’  I really think you 
have to look at an individual case by case basis.  There are many women like this who 
have been in monogamous relationships for many years and now they’re going to be back 
out in the dating scene, ya know?” (3 – APRN, ObGyn) 
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Another nurse practitioner also experienced it in her practice, and expressed her own feelings on 
the matter while also explaining that she was even apart of some of the data soon to come out on 
the older female population: 
 “I wish it was offered for patients later.  I think the 26, I know they’re looking at it, 
 because I’ve actually been apart of some preliminary data coming out on Gardasil® for 
 older women.  It doesn’t stop at 26!” She goes on later to explain, “Hopefully it will be 
 offered for older women.  Women who are HPV negative who are older, because I think 
 that’s a population that would benefit from the vaccine.  I see that population, that’s sort 
 of my point, is that there is a populace that you know… people get married young, enter a 
 monogamous relationship, and then split-up; that would be a population that I think 
 would be… And I have seen that in my own practice, so I think that’s an unaddressed 
 segment of the population.” (7 – APRN, Family/Internal) 
 
Another provider brought up the issue of recommending vaccination to females over age 26 even 
despite the FDA range: 
 “And of course the adolescent cervix is much more prone to transfer of HPV than the 40 
 year old cervix.  But still, if I had a 40 year old virginal patient who was becoming 
 sexually active I’d definitely recommend it!” She goes on to state later, “I actively 
 recommend it for virginal women and girls.  I offer it to everybody.  And that’s based on 
 the data that the efficacy is cut in half in women who are active.” (5 – APRN, ObGyn) 
 
It is interesting to note that one of the providers stated she would recommend the vaccine outside 
the FDA recommendations.  Unfortunately, it is unknown whether or not she has actually 
administered the vaccine to a female over the age of 26; or if any of the providers in this study 
have.  
Young Males and the HPV Vaccine 
 Another population that was brought up, which falls outside the FDA’s guidelines, is that 
of young boys.  This group was brought up less often than the older women, but it is still a 
significant issue gaining media attention.  Although males cannot get cervical cancer from HPV, 
they pass it on to their female partners, who can then be affected by it.  Also, some studies are 
investigating whether males may benefit from prevention of genital warts, and in very rare cases, 
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penile cancer.  One provider brought up the idea of vaccinating boys when asked if he had any 
other comments at the end of the interview: 
 “You know what, there’s one other thing you didn’t ask about, that I don’t know if you 
 want to include this, but, what about the idea, about how people feel about giving  it to 
 males?  I mean I think there’s no reason why it shouldn’t be offered to males as well!  
 Because obviously, that is how the females are mainly getting it!” (1 – MD, Pediatrics) 
 
Another provider also mentioned males, along with some interesting speculations about gender 
differences.  She explained: 
 “I think every kid should have it quite frankly.  And this means the boys too!  Which is in 
 the works.  What would be a really interesting study is once the boys come out with being 
 approved, how many of the parents are resistant to having the boys vaccinated as opposed 
 to the girls vaccinated.  That would be a very interesting gender discordant opinion.  I bet 
 a lot of the mothers would rather have their boys vaccinated sooner than their girls, 
 because they think of their little girls as angels, and the boys they know are not [laughs].” 
 (9 – MD, Family/Internal) 
 
It is interesting that she would speculate boys being vaccinated sooner, and perhaps implying 
more often, than girls.  The final provider to bring up male HPV immunization initiated the topic 
when asked how he felt about federal mandates, which will be discussed in more detail during 
the main controversial issues theme.  He notes: 
 “Fine, as long as I can give it to the guys too!  I don’t think it should be mandated just for 
 girls.  You can’t mandate until you’ve got universal coverage.” (4 – MD, Pediatrics) 
 
From his response, it can be assumed that this provider would approve of male HPV vaccination 
using Gardasil® and would administer it in his practice. 
 Another interesting point to note is that all the respondents who brought up male 
vaccination worked with a pediatric population.  Two of the participants specifically specialize in 
pediatrics, and the other is certified in family medicine, but stated that she saw patients as young 
as infancy.  As previously mentioned, the internal/family provider was one of the respondents 
who stated that she felt actual pediatricians were slow on the uptake of the vaccine (9 – MD, 
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Family/Internal).  Of the two pediatricians, one mentioned that he did not take an active part in 
recommending the vaccine to patients, though he did administer it (1 – MD, Pediatrics), and the 
other mentioned waiting about 18-20 months after FDA approval before administering (4 – MD, 
Pediatrics).  However, according to these findings, they were both more than willing to vaccinate 
males if and when the time comes and brought the issue up of their own accord during the 
interviews. 
 Shifting focus from the FDA guidelines, I mentioned above how some providers brought 
up the issue of being parents themselves, and having to make the vaccination decision.  A main 
theme that arose from the questions was why these providers felt patients and/or guardians might 
refuse the vaccine, or what experiences they have had when patients do decline to get it or seem 
not to want it. 
4) Provider Feelings about Patients’/Guardians’ Attitudes towards Gardasil® 
 When it comes to healthcare, the opinion of the provider is extremely important.  As we 
have seen, all the providers in this study administer Gardasil® to their patients.  However, it is 
not always that simple.  Patients may have their own feelings on the vaccine that do not 
necessarily coincide with the healthcare professional.  In this section, providers’ feelings and 
experiences with refusal or skepticism of the vaccine are discussed. 
 With Gardasil®, an important dynamic is created unlike that of most other vaccines.  In 
this case, the age group recommended for vaccination runs from an age at which parental consent 
is required to one at which female patients are old enough to obtain the vaccine on their own.  So 
the providers are commenting on why they believe either patients and/or guardians refuse or 
question the HPV vaccine.  
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Knowledge and Information 
 One of the first issues mentioned involved patient information or knowledge about 
Gardasil® and HPV in general.  One of the nurse practitioners commented on the sheer lack of 
knowledge she experienced with her patients which only recently began to turn around: 
 “Thank God Gardasil® has come out as far as being able to teach people about HPV!  
 Before Gardasil® nobody had any idea and the first thing when you call them up and told 
 them they had an abnormal pap and it might be a sexually transmitted disease, they like 
 went berserk on you.  At least now they’ve heard about it and they understand it and it’s a 
 little bit easier to discuss.” (3 – APRN, ObGyn) 
 
Although knowledge of the actual existence of HPV may be improving, other providers 
mentioned lack of knowledge and information with regards to Gardasil® research in the 
following quotes: 
 “Because they’ve only recently heard of it, and they’re assuming that it’s a new untested 
 vaccine, which is not the case!” (1 – MD, Pediatrics) 
 
 “Patients come in and talk about them [commercials], and it’s really not productive, it 
 doesn’t help inform them it just… You know, there might be a good drug and the 
 television will have them scared about side effects that really are not consequential.” (2 – 
 MD, Family/Internal) 
 
The above provider brought up the issue of patient fear in her response, which emerged as 
another main sub-theme to be discussed shortly.  She also mentioned the media, a common form 
of information for potential patients.  There are multiple media through which patients can obtain 
Gardasil® information, but providers worried that these modes were not founded in research or 
evidence-based.  One pediatrician explained: 
 “Keep in mind if it bleeds it leads.  And that is how newspapers, etc. get your attention.  
 ‘Cause they’ll give you a blurb and then that’s it.  It’s not in the best light obviously… 
 You know, it really depends on the source.  You go on the web, God knows what opinion 
 you’re gonna get.” (4 – MD, Pediatrics) 
 
Another provider explained that she felt alternative sources of information were acceptable, and 
even important in forming ones’ opinion, but again, evidence-based was key: 
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 “Well, you know, I really think that people should be able to get as much information as 
 they can and from a lot of different sources, and I don’t want to be the sole source of 
 information for people.  So I think the discussion is valid, but the sort of alarmist stuff 
 about people dying from Gardasil®, I think that’s a little hard to sift through.” (5 – 
 APRN, ObGyn) 
 
A physician implied a similar response: 
 “Sometimes you need to look at a number of sites to get where all those points of  light 
 intersect, and then make your best assessment of those.  So, people that are way out there 
 you can throw away.  Unfortunately, many patients don’t do that.” (6 – MD, ObGyn) 
 
He specifically mentioned the feeling that patients may not be getting adequate or accurate 
information.  Another nurse practitioner expanded on the kind of information that can be out 
there, and the importance, again, of research and evidence: 
 “I find across the board the information is only as good as the source.  So you can find 
 good information out there and bad information.  It’s like the vaccines for, you know, 
 people saying that it’s linked to autism.  That the MMRs [measles, mumps, and rubella
 immunization] are related to autism, if you can find a site out there that will tell you it is, 
 and it’s been shown in study and study and study that it hasn’t been!  So you can find that 
 kind of thing with the HPV vaccine too.  I just think that I want to caution people about 
 being very careful about where they get their information.” (7 – APRN, ObGyn) 
 
 Overall, it seems that providers believe many patients and/or guardians who refuse the 
vaccine, or raise questions about it, may not have an adequate amount of information, or 
information that providers would consider valid.  The issue of research is brought up later on 
when discussion of “Why Provider’s Choose to Vaccinate” is investigated. 
Fear 
 Fear was the most commonly cited reason for refusal or skepticism of HPV vaccination.  
There were many different kinds of fear explored by the providers, many of which link back to 
the sense of misinformation or inadequate resources.  One provider broadly stated: 
 “I think that there are some people who are reserved, there are a lot of people who are 
 very afraid of the medical community, and they hear a lot of things about drug companies 
 just want to make money, and they have some un-informed un-realistic fears, and 
 sometimes that overrides any information you can give them.” (2 – MD, Family/Internal) 
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More specific fears ranged from sexual promiscuity, to side effects and safety, as well as just 
needle phobias.  It is interesting to see the wide variety of possible fears that providers felt might 
be at the root of some patients’ or parents’ negative attitudes toward Gardasil® and/or decisions 
not to be vaccinated or have their daughters vaccinated.  With regards to sexual promiscuity 
specifically, the following quotes illustrate the providers’ views of parental concerns: 
 “The other reason is because they all say, well, the parents will say, ‘Well my daughter 
 isn’t promiscuous so why does she need it?!’” (1 – MD, Pediatrics) 
 
 “I had a patient the other day who told me that her husband really did not want the 
 daughter vaccinated, more I think out of that whole idea of he really didn’t want to think 
 about his daughter being sexually active.” (3 – APRN, ObGyn) 
 
 “I think a lot of them kind of hope that their child isn’t going to become sexually active, 
 and if they don’t give them the vaccine then it won’t happen.” (9 – MD, Family/Internal) 
 
 “And then sort of, all the religious right concern that it’s going to make people 
 promiscuous, which I think is false.” (5 – APRN, ObGyn) 
 
 “I think there are a subset of parents that feel as thought by administering a vaccine for a 
 sexually transmitted disease, that that will somehow open up the flood gates for sexual 
 promiscuity.  I think that that’s been marketed to some parts of the population.” She later 
 says, “I think that there’s a subset of the media, sort of the really conservative that’s 
 portrayed it as sexually promiscuous; I find fault with that.”(7 – APRN, Family/Internal) 
 
Many of these beliefs seem to be speculation.  It is unknown if any parents or patients actually 
expressed such feelings. 
 Fear of duration, or more so concern that the vaccine might not last long enough, was 
also an issue.  As previously quoted, one provider (7 – APRN, Family/Internal) was withholding 
vaccination for her daughter to get the added benefit of more years on efficacy data.  With regard 
to patients in particular, these providers explain: 
 “I think that some of the parents just want to wait and see, kind of what the long term 
 efficacy will be.” (7 – APRN, Family/Internal) 
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 “They have questions about it.  The biggest one is duration. We don’t know how long it’s 
 going to last.  Then I tell them, this is good for at least 10-12 years, but I can’t tell you 
 beyond that yet.” (4 – MD, Pediatrics) 
 
To an even lesser extent, one provider mentioned just a fear of needles: 
 “Some people, this is just shots, but I’ve had someone mention just say they can’t… 
 They’re so needle-phobic that they couldn’t get the concept of getting a shot voluntarily.” 
 (8 – MD, Family/Internal) 
 
 Aside from these reasons, the main fear seemed to lie with safety and side effects.  This 
was the most commonly mentioned among providers, as the following quotes show: 
 “I have experienced it, I have.  I think that some of it is fear.  I think that there is always 
 that fear of unknown, it’s new, and they want to wait.” (3 – APRN, ObGyn) 
 
 “Some people are worried about side effects and safety, things like that.  You get tons of 
 stuff about peoples’ safety concerns and safety issues.” (5 – APRN, ObGyn) 
 
 “A lot of the parents think their kid is too young, you know, the vaccine hasn’t been out 
 as long as they would like to see it.” (9 – MD, Family/Internal) 
 
Other providers were more specific, again referring back to a lack of scientifically-based 
information, demonstrated by their responses: 
 “I think that there are some misconceptions about the risks associated with any 
 immunization.  And they are frequently construed to this one.  So, the risks of autism for 
 instance, or other learning disabilities, or other issues that are not well scientifically 
 documented, but out there in the lay media and popular books are frightening to some 
 people.  I’ve heard people ask about it, you know, they’re not hook line and sinker sold 
 on those particular opinions, but it’s something, it’s a hurdle to cross.” (6 – MD, ObGyn) 
 
 “I mean, I think a lot of it is the same fear people have of any vaccine.  I mean I think it’s 
 the same reason that some parents choose not to vaccinate their children against mumps, 
 measles, and rubella; is that people have a fear that there’s some untoward reaction.” (7 – 
 APRN, Family/Internal) 
 
 The third and final sub-theme found with regards to provider feelings on 
patients’/guardians’ attitudes, was that of patient lifestyle, and not thinking they needed it.  For 
one, common misconceptions, such as the belief that because they were not yet sexually active 
they should not get the vaccine, were discussed previously in the results.  Patients or guardians 
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may not be aware that that is in fact the best time to get the vaccine.  One of the physicians 
commented: 
 “Well, women who are not sexually active yet, a lot of times don’t want to get it because 
 they don’t feel they need to.  They can’t think preventative.” (8 – MD, Family/Internal) 
 
Also, going back to parents, a nurse practitioner explained: 
 “You know, they think, why give a vaccine if their child’s not sexually active, or they 
 actually believe will never become sexually active?” (7 – APRN, Family/Internal) 
 
Other specific lifestyle beliefs were mentioned as well.  Another nurse practitioner stated: 
 “I mean some girls say, ‘I’m gonna marry somebody whose virginal, I’m virginal, it’s 
 never going to be an issue for me.’  Some girls are pretty adamant about that.  I suppose 
 I’m more of a realist, or maybe a cynic [laughs], you know?  When somebody tells me, 
 ‘I’m going to marry somebody who’s never had sex’ I sort of think, well, even in a 
 perfect world, even if that’s for religious reasons, what if you marry somebody who’s 
 been married before and their wife died… You never really know what you’re going to 
 be exposed to.” (5 – APRN, ObGyn) 
 
 Taken together, patients’ information and knowledge of HPV and Gardasil®, along with 
varied fears and lifestyle beliefs, were the three main reasons providers felt patients may choose 
to delay or not get the vaccine.  To offset these attitudes, whether perceived or actually 
experienced with patients/guardians, the next theme instead demonstrates why providers 
themselves feel compelled to use Gardasil®. 
5) Providers’ Choice to Vaccinate Against HPV 
 Again, all nine providers in this study stated that they administered the vaccine to their 
patients.  Two main themes repeatedly came up among provider responses, as to why they 
choose Gardasil®: research, and prevention of cervical cancer. 
Research 
 As demonstrated throughout much of the previous results discussion, research and 
evidence-based literature was a huge factor with a majority of providers.  Across specialties and 
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roles, most providers expressed belief in the importance of an evidence base, as the following 
quotes illustrate: 
 “I’d say peer-reviewed articles have led me to this decision.” (1 – MD, Pediatrics) 
 
 “I believe my peers, the research people, that’s about it, reading the literature is 
 important.” (4 – MD, Pediatrics) 
 
 “Overall opinion, I mean I went to a couple of seminars before on HPV and the vaccine, 
 and the statistics were wonderful and I thought it was something that we should be 
 doing… The FDA approved it, so, they have statistics to show that it helps number one, 
 and that it doesn’t harm.” (9 – MD, Family/Internal) 
 
 “The research, the evidence… Initially the reporting of the adverse events was just a 
 question, there was no concrete evidence that they were valid reports… Now the most 
 recent data shows that there are not any adverse effects.” (5 – APRN, ObGyn) 
 
Some quotes that stood out in particular include: 
 “Well, I like to practice evidence-based medicine, so I think that my decision is based on 
 evidence-based research that shows that the vaccine is safe and effective… It’s also FDA 
 regulated so you know they can’t make claims that they don’t have the research to 
 make!” (3 – APRN, ObGyn) 
 
 “Research!  Research, it’s all evidence-based, and if you go to good clinicians that’s what 
 they’re driving themselves by.  And the data are overwhelmingly supportive at this time.” 
 (6 – MD, ObGyn) 
 
The next reasoning was on a much more personal level.  Especially within obstetrics gynecology 
and family/internal medicine, they have experienced the hardships, both emotional and physical, 
with regards to HPV and cervical cancer. 
Prevention of Cervical Cancer 
 One physician abruptly stated: 
 “I think that if we have a chance to prevent cancer we should!” (2 – MD, Family/Internal) 
Many providers also drew upon their own personal experiences with patients who had abnormal 
cells found in their cervix, and then had to face treatment to stop cervical cancer from 
developing.  A particularly illustrative quote explained: 
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 “I think that from a more personal stand point is that as a provider who has been doing 
 this for so many years I’ve seen the devastating effect of HPV in young girls who have 
 gotten cervical dysplasia and then had to go on and have LEEPs or Cons [treatment for 
 abnormal cell growth in the cervix] and then have become what our industry calls, you 
 know, obstetrical cripples because they can’t maintain a pregnancy because they don’t 
 have enough cervix left to hold onto a pregnancy because people have been hacking away 
 at their cervix to prevent them from getting cervical cancer.” (3 – APRN, ObGyn) 
 
Another provider spoke of her own experiences with patients, and the importance of following a 
preventative healthcare model: 
 “I think just from, as a healthcare provider I see so many women who have suffered the 
 effects of HPV, so if there’s a vaccine or anything that as a healthcare provider I can 
 provide my patients with that could prevent a long term sequel of HPV, with minimal 
 consequences, I would be happy to provide that.  And I think as a nurse practitioner, I 
 think the medical model, or the nursing model is to be a steward of preventive care, and 
 that [the vaccine] would be part of a preventive care model.”  She goes on to say later, “I  
 have seen the consequences of HPV, and I think that if you have ever taken care of a 
 woman who has succumbed to cervical cancer, or has had to have repeated colposcopys, 
 or has had to have a hysterectomy, or the cost both emotionally and physically is huge, 
 and if there’s something that can be done to prevent that…” (7 – APRN, Family/Internal) 
 
One of the family/internal providers, who works specifically with college students, also brought 
up her experiences: 
 “Seeing so many effects from HPV, and anything that might decrease incidence of HPV 
 is great in my book… Since I do colposcopy exams where I examine the cervix and have 
 to do biopsies, it’s painful to put these young people through this.  And I don’t like 
 putting them through this.  Any anything that might… getting chunks of your cervix 
 biopsied is not a fun thing.” (8 – MD, Family/Internal) 
 
The healthcare provider mentioned earlier who works with patients from age 0-death, explained 
seeing all types of spectrums because of this, and added to what previous providers have said in 
even greater detail: 
 “I think that we would eliminate a lot of the angst, because you know, even if it’s not 
 cervical cancer, there’s anxiety and inconvenience in terms of having to have other 
 cervical surgical procedures, or more frequent pap testing, and more worry about, “Well, 
 is it ok!?” And all this kind of thing.  And I think that’s the beauty of the vaccine too; it 
 will eliminate in the future generation [most] of that garbage… so that we’re not, you 
 know, making women crazy about an abnormal Pap that really doesn’t have to happen.  
 And you know, honestly I have not diagnosed cervical cancer in my practice, but I’ve 
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 seen a lot of CIN, cervical intraepithelial neoplasia, which is dysplastic changes in the 
 cervix, precancerous changes of different levels and all that sort of thing.  And that I 
 think is what I hope to see eliminated in the future, so that women don’t have to be put 
 through as much of that kind of, ‘Oh, no, do I have cancer?!’ or, ‘Is it precancerous and I 
 have to have this procedure done?’… So I think that kind of stuff, the vaccine should in 
 the future eliminate a great deal of.  Which is a good thing!” (9 – MD, Family/Internal) 
 
These explanations were some of the most descriptive and personal accounts throughout the 
interviews.  Providers made it clear that evidence-based research and clinical experience with the 
virus were huge factors in their decision to administer Gardasil®. 
6) Provider Opinions on Other Controversial Issues 
 An article by Karen Houppert (2007) outlined some of the major controversies currently 
plaguing Gardasil®.  The providers were asked how they felt about some of these issues.  We 
have already covered the young age range, with the FDA guidelines stating providers could start 
immunization as young as nine.  Other concerns stem from sexual activity, something that was 
touched upon under parental attitudes, as well as pharmaceutical motives and possible mandating 
of the vaccine in the United States. 
Sexual Activity 
 Providers were asked if they believe administering the vaccine to females, who are not 
yet sexually active, will cause them to have sexual intercourse before they normally would have.  
The overwhelming response from all participants was that it did not.  Some were short and brief 
in their answer, as the following quotes show: 
 “No, absolutely not.” (1 – MD, Pediatrics) 
 “Absolutely not!  That’s another myth.” (4 – MD, Pediatrics) 
 “That would be no.” (7 – APRN, Family/Internal) 
 “No!” (8 – MD, Family/Internal) 
Another provider took on a more sarcastic, joking tone: 
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 “No.  And it probably won’t lead them to getting a pilot’s license either, I mean, come 
 on.” (2 – MD, Family/Internal) 
 
Other providers went more in-depth about why they felt it was not an issue.  Sex education and 
contraception was a common theme, as shown in these gynecologists’ quotes: 
 “No, I don’t.  That has been the argument since birth control pills came out in the 1960s.  
 It is the same reason why we do sex education the way we do.  I mean you have Sarah 
 Palin, she was a perfect example of how not teaching sex education in high school does 
 not stop your daughter from getting pregnant!  I mean, that, you know, [laughs] the right 
 wingers really want to make it out like… people who feel that that’s really a political 
 religious choice really they have not had good outcomes for their, ‘Let’s bury our head in 
 the sand’ kind of, ‘Oh it’s not gonna happen if we don’t talk about it,’ and I think that’s 
 where that sort of theory comes from.  It doesn’t work!” (3 – APRN, ObGyn) 
 
 “No, not at all.  None of the evidence supports that.  It doesn’t support that giving out 
 condoms makes people sexually active earlier, so, or birth control!  It really shows that 
 when you prescribe birth control pills, it does not make people more likely to be sexually 
 active.” (5 – APRN, ObGyn) 
 
 “I don’t… And you know what, if discussion about sex leads to sex, you know, it 
 probably leads to more responsible sex, because it should include all of the discussion 
 about things that are onerous about it.  And in fact it may delay sex as much as people 
 say it encourages it.” (6 – MD, ObGyn) 
 
A family/internal physician brought up an interesting argument, going back to age range: 
 “No!  Most of them don’t even know what it is or about, and they just think it’s another 
 shot, something good to do.  I mean, ask a kid when they had their last tetanus or 
 pertussis vaccine... They’ll say ‘What? Did I ever have that?’ and they’ve had it a zillion 
 times, so, you know, most of the time they just know they have a shot and it’s gonna hurt 
 and they have to do it, but they don’t necessarily, usually know what it is, or inquire or 
 care.  Unless they have a specific interest.  I could see some populations where older girls 
 would come in and ask without their guardians, but I haven’t seen that in my own 
 practice.” (9 – MD, Family/Internal) 
 
She also brings up an interesting idea around older females.  The provider working with a 
college population expanded on her previous “No” answer: 
 “I don’t.  But then I have a very narrow range of patients that I see.  In some patients it 
 may, they may be asking for it because they’re thinking of becoming sexually active.  But 
 it and of itself, no I don’t think so.” (8 – MD, Family/Internal) 
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Going back to the comment that children are not even aware of what they are getting immunized 
for, another provider agreed: 
 “If you don’t want to give it as sort of a “It’s okay for you to have sex” kind of thing, 
 then it’s better off giving it to your nine year old who really doesn’t quite understand the 
 concept of what it is they’re getting… They’re used to it, at 10 they get their tetanus 
 booster anyways, so if you did the tetanus booster and the Gardasil®, I think that that 
 would be a perfect time for them to get it!” (3 – APRN, ObGyn) 
 
Pharmaceutical Profit; Merck 
 Much of the outcry over the vaccine has stemmed from concerns that Merck & Co. are 
not concerned with girls’ safety, but rather just making profits.  Some providers felt that there 
was more of a concern for profit, but didn’t seem to think it was much of an issue, as the quotes 
show: 
 “Come on [laughs], I don’t live in a fairy tale world.  Of course they’re out to make 
 money, everybody wants to make money.  Is there some altruism there?  I’d like to 
 believe that there is, but you know, if they had figured out how to make Viagra back 
 when Viagra came out, I’m sure they would be just as happy.  Are they able to get people 
 to believe and fund things more for them because there’s some issue of altruism?  
 Perhaps, and I’m sure that they will be forced in some way either through social pressures 
 or so forth to give back some to the community.” (3 – APRN, ObGyn) 
 
 “Well obviously they’re primarily concerned with money.  And after that comes safety, 
 etc.  They’re in business to make money…” (4 – MD, Pediatrics) 
 
 “I certainly believe they have a concern for profit [laughs].  But you know, hopefully 
 they have some concern for women’s health as well.” (7 – APRN, Family/Internal) 
 
A majority did outwardly state that they felt this was not an issue as far as they were concerned, 
or it was an issue that had nothing to do with their own clinical use of Gardasil®.  Their 
responses explain: 
 “Oh I think that they’re concerned with profits.  You know, but I mean they happened to 
 hit upon a vaccine that is safe and useful.” (1 – MD, Pediatrics) 
 
 “I would hope they’re concerned with safety, and I’m sure that they want to get the 
 money back that they did in research, but I don’t know that that’s their primary goal for 
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 doing this… It’s unrelated to the individual who would benefit from it!” (2 – MD, 
 Internal/Family) 
 
 “Well, it depends on who’s they?  It’s a corporation.  So, of course they’re concerned 
 about profits and that’s the bottom line, and I think that’s what drives corporations.  But I 
 don’t really care either!  If it’s an effective, safe vaccine, that’s great.  I don’t care what 
 Merck, as a corporation, what their motivation is.” (5 – APRN, ObGyn) 
 
Several other providers explained how safety and profits were intertwined, so patients and 
guardians should find comfort in the fact that Merck© is essentially obligated to worry about 
safety regardless, stating as follows: 
 “I think they’re obligated to be concerned with all of those.  They are a for-profit 
 company, and they make no bones about it, and neither should we.  We know that they’re 
 out to make money or otherwise they’d be giving it away, and they’re not.  I don’t have 
 any confusion about that… They’re worried about girls’ safety because you know the 
 people that sit around a board table are concerned about the populace as individuals, but 
 they’re more concerned that those individuals might raise a class action lawsuit against 
 Merck and put them under.  That would be my inclination, and that’s not to suggest that 
 they are bad individuals or bad people, but that their job is to run a business, and to run it 
 as safely as possible and liability is one of the things that will sink a business extremely 
 quickly!” (6 – MD, ObGyn) 
 
 “They’re definitely concerned with profit, but you can’t say that they’re not concerned 
 with safety because it’s gonna look bad on their profit margin if it’s a bad vaccine!” (8 – 
 MD, Family/Internal) 
 
When asked if the drug was being pushed too hard or too soon by the company, every single 
participant said no, that it wasn’t an issue.  Some felt it should be pushed, or perhaps the pace of 
introduction was even helping. 
A Federal Mandate 
 A federal mandate is an order from the central government that requires all state and local 
government to comply.  Once the overwhelming research came out about the efficacy of the 
vaccine, many people felt that it could be mandated in the interest of the public health.  However, 
many other people felt that mandates were completely out of the question.  With that being said, 
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this particular section was the most varied in terms of provider responses; they fell on both sides 
of the spectrum.  Some flat out felt it should not be mandated: 
 “I don’t think any, I don’t think it should be mandated.” (1 – MD, Pediatrics) 
 
 “I guess I’m not a fan of mandates.  You know, I think that you should just… Yeah, that 
 just rubs me the wrong way.  And so I think that if you, you can’t force people to get 
 vaccines you know.” (5 – APRN, ObGyn) 
 
Others were against a full-out mandate, but willing to accept an opt-out requirement, in which 
patients would be administered the vaccine unless a parent states otherwise.  Two providers 
clarify: 
 “I like the opt-out option a lot more than, you know, a federal mandate that you will be 
vaccinated if you plan on surviving, or something, punishable by what? Deportation?  I 
don’t think that that’s a good idea.  We live in a country where we uphold ourselves as 
people who value individual judgment and individual freedoms.  So, for that reason alone 
you can’t mandate these kind of things.  Having said that, we mandate helmet use.  We 
mandate seatbelt use.  We mandate things for people’s safety on a regular basis.  Should 
we be doing that?  I would argue no.  Live free or die – I’m a New Hampshire guy 
[laughs] so I don’t think it should be mandated that they go before school.  I don’t think it 
should be included among the ones that are communicable diseases that affect the 
population much more readily, respiratory born diseases for instance, so I don’t agree 
with that.” (6 – MD, ObGyn) 
 
 I don’t think it should be mandated.  I think opt-out maybe.  I think it should just be 
offered.  I mean I think it’s… I think mandated from a societal stand point is pretty… 
‘Cause it’s not, I mean it would be… Oh gosh that’s tough… I mean I think it should be 
opt-out I guess.” (7 – APRN, Family/Internal) 
 
The above nurse practitioner is a good example of how hesitant and unsure many of the 
participants were when answering this particular question.  Another standpoint that fell 
somewhat in between was pro-mandate, yet still hesitant to flat out say so: 
 “You know if you compare it to other vaccines, the reason that other vaccines are 
 mandated is because these diseases are contagious in a way that a person can get them 
 without doing anything, without having sexual intercourse or without.  So, that’s a 
 difficult question.  I suppose if push came to shove I would lean towards having it 
 mandated.” (2 – MD, Family/Internal) 
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 “As a public health minded person, I can easily rationalize doing that [mandating it] 
 considering the association with cervical cancer and the health costs to the population and 
 health care system.  So I can see doing it.  On a political basis, I can see that being 
 difficult.  You’d have to have people be able to opt-out without penalty, because of the 
 religious objections of, it’s making them more sexually active – It’s hard to, I would like, 
 I could easily see backing it being mandated, unless you opt-out because of religious 
 objections for example.  I know, we’ve added so many vaccines to childhood vaccines, 
 gosh, my kids if they were just being born now would be like, pin cushions!” (8 – MD, 
 Family/Internal) 
 
One provider raised an excellent point with regards to gender.  He was certainly pro-mandate, 
but only if it was universal: 
 “Fine, as long as I can give it to guys too.  You can’t make it mandatory unless you make 
 it universal, and that means giving it to males too.  I don’t think it should be mandated 
 just for girls.  You can’t just pick out this one and that one and say they all should have it 
 – it’s everybody or nobody.” (4 – MD, Pediatrics) 
 
Another pro-mandate physician explained her reasoning in a different light, which was not 
brought up by any of the other participants.  She explains: 
 “That’s a good question. It’s the question of when do you decide as a society that this is a 
public health issue.  You know, we do have requirements for school age children for 
measles, mumps, rubella, and for chicken pox and for other sorts of things which on some 
level may actually cause less of an issue.  HPV is not as obvious a disease, it takes time to 
develop cervical cancer, it takes time, it’s over time that you see changes.  And it’s also 
over other exposures that people are exposing other people to it as well, which, you know 
is a subtle issue there.  You know, it’s not like you’re contagious, you give someone 
chicken pox in 2 weeks.  You can give someone HPV and they have that around, and 
then maybe 10 years later they start to have some changes on their Pap tests.  So, I think 
it would be a good idea.  I think every kid should have it quite frankly.” (9 – MD, 
Family/Internal) 
 
Finally, the most illustrative and descriptive quote came from a provider who vehemently 
supports the idea of a mandate, citing many important reasons for doing so: 
 “It would be perfect. I think it would take away the parental issues with it.  I mean, there 
are still, and you know it’s funny because as a midwife I try to be very respectful of 
people and their choices of what they want, especially in their childbearing years and 
through their labor and delivery and birth… and toward that end there are many of my 
patients, I wouldn’t say many, there used to be more, that really didn’t want to have their 
children vaccinated with anything.  And you know you try to be respectful of those 
people, but some of their, when you really listen to their reasons for not wanting it, 
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they’re not based in fact.  They’re based in fairy tale, and they’re based in fear.  And 
again, you know, I think if it was just, age 10 you got your tetanus and your Gardasil – 
There it is, it will go away!   
 It’s the same issue as to when about, 10-12 years ago, the state of CT mandated that we 
had to test every woman in pregnancy for HIV.  And if they refused to be tested, then we 
would test the baby when the baby was born.  And so, you know, I remember doing 
prenatal visits with these women and you’d have to spend 20 minutes going through, that 
you had to sign this consent, we’re going to test you for HIV, and blah blah blah, and 
now, you know, you check it off on the lab slip and nobody even questions it anymore!  
So I think that a tenure of time will definitely make this better.  But, I also think that 
mandating it just sort of takes away the… It’s in the best interest of the public health, 
which is what the HIV test does, it’s what, you know all of those things.  It’s the same 
thing with the chicken pox, I didn’t want my kids to get the chicken pox vaccine when it 
first came out,  but you know what, I’d rather have them get the chicken pox vaccine now 
then have the risk of getting it later on in life when it can actually be fatal.   
 As much as we don’t want to look at it because we’re so myopic in a sense, we have to 
look at the best interest of public health.  You have to at some degree look at that because 
you know you can’t say that this doesn’t effect… It’s just like the woman who just had 
the 8 babies.  You can’t see that in a vacuum, it will affect all of us ultimately in one way 
or another, and if you don’t believe it does you’re naïve. They’re already saying, from the 
impact of the insurance companies, and the costs to take care of these babies, we will all 
eventually pay for that because the rates of insurance are going to go up because there are 
cases like this.  So you know you can’t just say, ‘oh, that was her personal decision to do 
that,’ because her personal decision has a huge impact on everything else!  None of us 
live within a vacuum, we’re a society and we live together and we impact each other, and 
so, you know, doing the best that we can to prevent something like this [HPV, cervical 
cancer] from becoming epidemic, which it is in other countries…” (3 – APRN, 
Family/Internal) 
 
 As the quotes demonstrate, views differed quite dramatically from provider to provider 
on this issue.  This is clearly different from the previous themes and ideas discussed.  Mandating 
continues to be a controversial issue, not just in the media. 
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DISCUSSION 
 The following chapter will summarize the main themes and explain various patterns, or 
lack thereof, found among participants.  Previous research will also be included where necessary, 
with possible implications from these findings and future research recommendations. 
General Discussion 
 The healthcare professionals participating in the study varied tremendously with regards 
to their profession and area of specialization.  There were three nurse practitioners and six 
physicians, of whom two practiced pediatrics, three were in obstetrics-gynecology, and four were 
in family/internal medicine.  Despite this variation the findings show a relatively uniform set of 
overall practices and opinions.  Previous research has shown some differences among these 
various professions with regards to the vaccine (Duval et al., 2007). However, due to the 
qualitative nature of the present study, providers were able to offer both similar and different 
reasoning behind those initial thoughts and behaviors.  Also, it is possible the results found in 
previous studies were due to the timing of those studies, which were completed prior to FDA 
approval.  As noted by a number of this study’s participants, a slower acceptance by 
pediatricians, and differences by profession appear to have dissipated over time.  There were also 
a minority of ideas which instead elicited very diverse responses among the participants. 
 Using an open-ended interview approach allowed participants to expand on their 
opinions, without being limited to predetermined answers.  Since previous published research 
was performed before or during FDA approval, and was mainly quantitative surveys, these 
results give a more current picture of provider practices and experiences while also explaining 
why providers choose to vaccinate, and how they feel about the more controversial issues 
regarding Gardasil®. 
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General Attitudes, Opinions, and Practices 
 As providers discussed their initial feelings about the HPV vaccine during its approval in 
2006, many felt it was a great medical breakthrough.  Some did voice skepticism, but none of the 
participants expressed any outright negative opinions.  There was some difference in when 
providers actually incorporated the vaccine into their clinical practice, but when asked about 
their current views, all providers believed that Gardasil® was an important vaccine for patients. 
 With that being said, all providers stated that they currently administer the HPV vaccine 
to their patients on a regular basis, and all believed that it was both safe and effective in 
preventing cervical cancer linked to the four HPV strains immunized against, as much as the 
research showed.  However, although the current study found that 100% of this varied group of 
providers supported vaccination, the sample size does not support a generalization across all 
professionals.  Previous research examining intent to administer found a high number of 
participants stating they would vaccinate when the vaccine became available, but it was not 
across the board.  Presently, there may certainly still be providers who do not support the vaccine 
even after its FDA approval, though they were not included in this particular sample.  Future 
research will benefit from a larger sample size. 
 When meeting with patients, only one provider said that he did not actively bring up and 
recommend the vaccine when patients did not address it first.  When asked to expand, he become 
somewhat defensive and hesitated before stating that other medical assistants will often bring it 
up with his patients.  This reaction to the question might show that providers feel pressure from 
outside sources or feel they are expected to actively immunize their patients.  Future research 
exploring this further would be an interesting topic.  This pediatrician was a strong proponent of 
the vaccine, so it was somewhat unexpected that he did not actively bring it up.  Some of the 
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earlier previous research has shown that pediatricians anticipated giving the human 
papillomavirus vaccine to older patients rather than younger ones, usually around age 13 or 
higher (Kahn et al., 2005, Daley et al., 2006).  Also, seeing children from age zero to early 20’s 
leaves a large number of patients who come in that are much younger than the FDA guidelines.  
This may make it harder for the pediatrician to adopt an active recommendation schedule.  
However, the other pediatrician in the study did say he brought it up when appropriate.  Future 
research would benefit from looking more closely at the exact processes pediatricians, as well as 
other healthcare professionals, go through when meeting with patients, and why.  Some of the 
participants in this study had even devised certain tactics or routines when discussing Gardasil® 
with patients and/or their guardians in order to explain their beliefs about its benefits, safety, and 
efficacy. 
FDA Recommendations for Females Ages 9-26 
 Many interesting findings emerged with regards to the particular theme concerning FDA 
age range.  As mentioned before with the pediatricians, previous literature has consistently found 
that providers across all medical disciplines would prefer to vaccinate, or were intending to 
vaccinate, against sexually transmitted infections more often as the age of the female patient 
increased.  These studies looked at nurse practitioners, gynecologists, family physicians, and a 
majority of pediatricians (Mays et al., 2004; Raley et al., 2004; Riedesel et al., 2005; Kahn et al., 
2005; Daley et al., 2006; Duval et al., 2006).  The current study found a very different pattern.  
Although some of the participants expressed that nine seemed young, and most did not 
frequently vaccinate at that age, none would oppose administering it at that age.  Those few 
providers who did see a more high-risk population did administer around nine, and the rest stated 
they had no problem with starting at that age when appropriate.  It was completely dependent 
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upon the patients’ sexual history and the demographics of their patient population.  Two very 
common themes among the providers were that patients should absolutely try to receive HPV 
vaccination before any onset of sexual activity, and secondly, again, the importance of knowing 
one’s patient population. 
 It is important to note that all previous literature was performed before or during FDA-
approval; this may be responsible for the noted difference in accepted age for administration.  
After over two years of clinical use, Gardasil® may be better understood and accepted in the 
medical community.  Several providers even mentioned feeling that it was more of a routine now 
than anything, and that all the “hullabaloo” from the beginning seemed to be dying down.
 Another interesting finding was the desire to vaccinate outside the FDA guidelines, both 
for boys and for women over age 26. More providers mentioned the issue of vaccinating older 
females.  Although the vaccine has not yet been FDA-approved for this population, providers 
told stories of their experiences with such patients and expressed a longing to give them 
Gardasil®.  One provider even expressed an inclination to give it anyway, and stated that she 
would actively recommend the vaccine to a virginal patient regardless of age.  These findings are 
not consistent with previous research which claims organizational endorsement of the 
administration of the vaccine is one of the most important factors in guiding healthcare 
providers’ intentions (Mays et al., 2004; Raley et al., 2004; Riedesel et al., 2005; Kahn et al., 
2005).  The previous research focused on actual Gardasil® endorsement rather than guidelines, 
but it would be interesting to see in future research if there are many providers who are already 
vaccinating boys and older women before actual approval.  Providers may be well aware that the 
FDA is not approving these populations mainly due to cost-effectiveness issues, not on actual 
 52
concerns of safety.  The above mentioned research also showed that providers were more willing 
to vaccinate females over males, another finding that may be changing with time. 
Perceptions of Patient/Guardian Attitudes 
 Providers discussed their experiences with guardian or patient refusal/skepticism of the 
vaccine, as well as possible reasons that might not be outwardly stated to them.  These findings 
were relatively consistent with previous research reviewed by Zimet et al. (2008) which found 
that, “Across all studies, opposition to HPV vaccine was associated with concern about 
vaccination leading to sexual disinhibition, viewing one’s child as being at low risk for infection, 
and worries about vaccine safety” (p. 227).  It is unknown how often the providers in this study 
encountered opposition to the vaccine, whether it was daily, every week, or even less often, and, 
indeed, whether the opposition is real or was just perceived or assumed by the provider.  
Previous research found that most parents find HPV vaccines to be acceptable and want their 
children to be vaccinated (Olshen et al., 2005; Dempsey et al., 2006; Constantine & Jerman, 
2007).  Future research should examine this phenomenon of perceived or real parental opposition 
to gain better insight into what providers are experiencing with patients and their guardians now 
that the vaccine has been in clinical usage for over two years.  Post-FDA approval studies will 
continue to be important in order to see if any changes are taking place as time progresses. 
Why Providers are Vaccinating 
 There have been no published studies to date which explore why providers are choosing 
to vaccinate.  Again, the open-ended nature of the interviews allowed providers to explain their 
experiences and feelings in greater detail, especially after actually being able to give the vaccine 
within the last few years. 
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 The two main findings that came up were a firm belief in the research, and provider 
experiences with HPV and cervical cancer patients.  The literature was a constant factor for all 
providers, whether it was for their own practices, or with regards to the information being 
obtained by patients.  They felt that evidence-based research was one of the most important 
aspects of accepting and administering an immunization; information that many patients may not 
obtain, or not realize is available.  Future research could look at how often patients are in fact 
receiving valid research data for Gardasil®, as well as possible initiatives to increase the 
availability of articles and journals outside the healthcare office.  The degree of reliance on 
evidence underscores the need for developing and widely distributing clear, unbiased 
information about medical treatment and applications of new prevention options. 
 The provider discussion of experiences treating females who have gotten HPV, which 
later developed into abnormal cell growth, was very eye-opening.  It is not often in the research 
that one sees such personal accounts of the actual physical and emotional tolls cervical cancer 
can have on patients and on the people who treat them.  The gynecologists and family/internal 
medicine providers all wanted to eliminate the devastation of telling women they needed an 
invasive procedure to prevent them from progressing into a more serious phase, as well as the 
sadness and pain associated with the direct procedures themselves.  The previous quantitative 
literature was not able to capture this illustrative side of the research which clearly pervades 
many of the providers’ experiences.  It may also be speculated that a possible explanation for the 
slower uptake of the vaccine by pediatricians mentioned by other providers, as well as the 
pediatric physician in the study who was not actively recommending, may be due to the fact that 
they do not often see or deal with the effects of cervical cancer and HPV in their patients. 
Providers who do experience this side of the illness may be more passionate about the 
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vaccination process.  Future qualitative research could examine this phenomenon further to gain 
a better idea of why certain medical professions are faster on immunization uptake, or more 
accepting of novel vaccines and medications based on their healthcare specialties.  
Other Controversial Issues 
 Sexual promiscuity, pharmaceutical profit, and a federal mandate are all debates currently 
surrounding Gardasil®.  The first issue, which maintained that the HPV vaccine could open the 
door to sexual activity for children, was overwhelmingly condemned by the participants in this 
study.  Each provider felt very strongly that the vaccine does not lead children to engage in 
sexual intercourse any earlier than they normally would have.  An interesting dynamic is created 
because many of these same providers felt that this was one of the issues parents had with the 
vaccine, though it is not known how often.  Upcoming research topics could investigate whether 
or not there truly is a major gap between parental and provider opinions.  To date, no studies 
have compared these two groups, despite the fact that they both have a large part in the HPV 
vaccination process. 
 Pharmaceutical profit was another topic of controversy in the media, though none of the 
providers in this study felt the orientation or motive of Merck© was of any real concern.  They 
all stated a similar belief that the company was out for profit, like any other business, but that 
should not be an issue.  They again pointed to the fact that the vaccine has proven itself to be 
both safe and effective, and therefore, any arguments about the pharmaceutical company are 
irrelevant.  When discussing whether Merck’s© previous arthritis drug, Vioxx®, which was 
pulled from the market after possibly causing multiple illnesses and deaths, would raise a similar 
possibility related to Gardasil®, one of the providers made an interesting point.  Rather than a 
fear of history repeating itself, it would make more sense to think that because of the previous 
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incident the company would work that much harder to make a safe and effective vaccine.  After 
all, if they are only concerned with profits, they surely would not want to make the same mistake 
twice. 
 The final issue, which elicited the most diverse responses, was that of federally 
mandating the vaccine.  All the providers made very good points as to why the vaccine should or 
should not be mandated for a specific age range, including children.  When asked if they felt the 
vaccine should be mandated, many of the providers seemed caught off-guard, as though they had 
not really given much thought to their own opinions beforehand; this may have influenced their 
responses.  Regardless, previous research has shown that the mandate issue is one of complex 
and varying opinions (Haber, Malow, & Zimet, 2007).  As time progresses, and as more research 
comes out on the vaccine’s safety and efficacy, perhaps the issue of mandating will no longer be 
as controversial.  Due to the conflicting responses found among the providers in this study, this 
political issue will be a rich area for future research.  Such investigations could lead to important 
policy recommendations as more information becomes available about not only safety and 
efficacy, but also possible universal approval of all genders and ages.  Healthcare providers are a 
huge part of the immunization process; therefore their practices and opinions will be important in 
the discussion of a future mandate.  As many of the providers stated, almost three years into 
clinical use, they have noticed greater acceptance of Gardasil®, a trend that may continue.  If this 
is the case, ongoing research will also be important in examining how opinions and 
administration of the HPV vaccine are changing, and why. 
Conclusions  
 There is no question that Gardasil® has risen to be among the list of society’s modern 
healthcare controversies.  Houppert (2007) stated it best when she explained, “How a medical 
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breakthrough for women set off a political firestorm” (p. 17).  Despite the wide range of opinions 
available to the general population, healthcare providers are the ones ultimately responsible for 
prescribing and administering the vaccine.  Thus, they are often the first people patients and 
guardians will go to, to ask questions about such immunizations or to get help sifting through all 
the information.  Smith et al. (2006) found that health care providers have a positive influence on 
parents to vaccinate their children, including parents who believe that vaccinations are unsafe.  
Therefore, it is essential to study opinions and experiences with Gardasil® among all healthcare 
providers who influence patient and parental decisions. 
 This study has certain limitations that can be improved upon in future research.  As 
previously mentioned, nine providers is a small sample size to work with, especially when 
broken down into a specific combination of training and specialty.  Future research would 
benefit greatly by including many more health care providers while utilizing the same diverse 
criteria and qualitative methodology.  Also, recruitment could be performed at a national level 
rather than just Connecticut in order to obtain a more inclusive view of the rest of the country’s 
medical practices and beliefs.  Such improvements would allow for greater generalization 
strength, and could also lead to new and important findings that were not captured in the current 
research. 
 Also, there is an issue of selection bias based on who was included.  Participants were 
health care providers who were willing to be interviewed by an undergraduate student without 
remuneration for the interview.  Thus, they may have more well-formed, consistent, and/or 
positive attitudes about Gardasil® and sought out the opportunity to express their opinion.  
Future research, again benefiting from a larger sample size, should use recruitment methods 
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which might increase the likelihood of participation from those providers who may not 
administer the vaccine. 
 Finally, the interview guide was relatively structured with regards to the questions and 
how they were asked.  Interview sessions were also relatively brief, as opposed to a multi-hour, 
very open discussion which can be an important part of qualitative research.  Future studies may 
need to offer a gift or monetary compensation to have longer, less structured interviews with 
providers.  The question guide could also be improved by including more in-depth questions 
about some of the themes that arose that were not previously accounted for.  Discussion focusing 
more on actual practices and experiences with patients and guardians would be beneficial in 
broadening the framework of a more current view of Gardasil® use in today’s society. 
 Despite these limitations, the study provides some important information not available in 
other sources.  The current study expanded on previous research by performing a more in-depth 
qualitative interview study.  This allowed participants to expand on their beliefs and explain their 
current experiences with the vaccine now that it has been approved for almost three years.  
Earlier research, as previously mentioned, was all performed before or during FDA approval so 
provider responses were based on their intentions rather than their actual thoughts and behaviors 
using Gardasil®.  Looking across more than just one medical profession and specialization also 
allowed for some interesting findings which may not have been discovered otherwise, or were 
not compared in other studies.  The fact that this group of providers had such noticeable 
uniformity across their responses will have significant implications for coming research on HPV 
vaccination. 
 It is hoped that the current findings might lend important information to those people who 
have not yet seen their healthcare provider about Gardasil®, are financially unable to, or are too 
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uncomfortable bringing up the issue with them.  Knowledge about how providers feel, how they 
make their decisions, and what they have experienced thus far with the vaccine could be 
disseminated to other provider offices, health agencies, schools, and programs which provide 
preventive services to a range of clients, including those who are less informed and/or unable to 
access certain resources.  
 Also, as more immunizations are in the works for other sexually transmitted infections, 
including HIV/AIDS and genital herpes, current research on provider opinions and practices with 
Gardasil® will be important in determining the possible uptake of such vaccines in the future.  A 
recent Center for Disease Control and Prevention study found that one in four female adolescents 
in the United States has at least one of the most common STIs  (Forhan, Gottlieb, Sternberg, Xu, 
Datta, Berman, & Markowitz, 2008).  This is a huge issue that society will no longer be able to 
ignore, and more research on healthcare providers will be essential in tracking the fight against 
such illnesses. 
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Appendix A: Interview Guide 
 
General Information:  
 Age? 
 Gender? 
 Number of years in practice? 
 Medical certification/title? 
 Specialize in? 
 Typical age range of patients? 
The Provider:  
 What did you initially think about the HPV vaccine, Gardasil®, when 
it was first introduced in 2006? 
     Have your views changed at all? 
 Do you currently administer the HPV vaccine to your female patients? 
     What has led you to this decision? (Probe; religion, personal  
     experience, drug companies, peers, research) 
 Do you feel the vaccine is effective in preventing cervical cancer? 
 Do you think the vaccine is safe to administer? 
 Do you actively recommend the HPV vaccine to your female patients 
and/or their guardians? 
     If so, how? 
 Do you bring up the vaccine with female patients/their guardians on 
your own, or do you wait for them to ask about it before voicing your 
opinion? 
     Why? 
 When meeting with female patients, how important is the issue of 
Gardasil® among other topics? 
The Patients:  
 Why do you think some patients and/or guardians choose not to get 
the vaccine?  Or have you experienced any who did not want it? 
     Do you agree with any of these reasons; or do you have any of 
     your own? 
 How do you think the media has portrayed the vaccine in a negative or 
positive way? 
     How accurate do you think such outside information is for 
     patients? 
 Have your patients ever experienced any negative side effects which 
they believe occurred because of taking the vaccine? 
Controversial Issues:  
 If you do administer the vaccine, at what age or age range do you 
think females should start getting Gardasil®? 
     What led you to choose this age (range)? 
     Do you agree with the FDA beginning the age range at 9? Why or 
     why not? 
 Do you believe administering the vaccine to females, who are not yet 
sexually active, will cause them to have sexual intercourse before they 
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normally would have, had they not had the vaccine? 
     Does your opinion change depending on the age of the female? 
 Do you believe that Merck, the drug company responsible for creating 
Gardasil®, is concerned with profits, or girls’ safety? 
 Is the drug being pushed too hard and too soon? (Probe; some have 
voiced concern that the pace of the vaccine’s introduction is 
jeopardizing its ultimate success) 
 How would you feel about the HPV vaccine being mandated for girls 
before they enter middle school?  Or an opt-out option? 
 Overall, any other comments? 
 
